<SEC-DOCUMENT>0001140361-25-031253.txt : 20250814
<SEC-HEADER>0001140361-25-031253.hdr.sgml : 20250814
<ACCEPTANCE-DATETIME>20250814162951
ACCESSION NUMBER:		0001140361-25-031253
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250814
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250814
DATE AS OF CHANGE:		20250814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CareTrust REIT, Inc.
		CENTRAL INDEX KEY:			0001590717
		STANDARD INDUSTRIAL CLASSIFICATION:	REAL ESTATE INVESTMENT TRUSTS [6798]
		ORGANIZATION NAME:           	05 Real Estate & Construction
		EIN:				463999490
		STATE OF INCORPORATION:			MD
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36181
		FILM NUMBER:		251219846

	BUSINESS ADDRESS:	
		STREET 1:		905 CALLE AMANECER, SUITE 300
		CITY:			SAN CLEMENTE
		STATE:			CA
		ZIP:			92673
		BUSINESS PHONE:		(949) 542-3140

	MAIL ADDRESS:	
		STREET 1:		905 CALLE AMANECER, SUITE 300
		CITY:			SAN CLEMENTE
		STATE:			CA
		ZIP:			92673
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ef20053958_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2025" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:cef="http://xbrl.sec.gov/cef/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:ctre="http://caretrustreit.com/20250814" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solution Inc.
         Document created using Broadridge PROfile 25.7.1.5324
         Copyright 1995 - 2025 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_6fe9c59c3933434f9c12ded4eb59cb63" contextRef="c20250814to20250814" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_108c278141424840a0514dab45f779db" contextRef="c20250814to20250814">0001590717</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="ctre-20250814.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20250814to20250814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590717</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-14</xbrli:startDate><xbrli:endDate>2025-08-14</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
<div style="line-height: initial;">
  <div><span style="font-size: 10pt;"> </span></div>

  <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/>
  <div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_0c76931bf96242c2a131651f32fc8f60" contextRef="c20250814to20250814">8-K</ix:nonNumeric></div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 or 15(d)</div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">of The Securities Exchange Act of 1934</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_fbf21a23a5704c10979f288eb909d041" contextRef="c20250814to20250814" format="ixt:date-monthname-day-year-en">August 14, 2025</ix:nonNumeric></div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_6c35c70d7a8b4e33bf1273ce47bcf9b0" contextRef="c20250814to20250814">CareTrust REIT, Inc.</ix:nonNumeric><br/>
    </div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Exact name of registrant as specified in its charter)</div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
    </div>

    <div style="font-size: 10pt;">
      <hr style="height: 2px; width: 20%; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

    <div style="text-align: left; font-size: 10pt;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 33%; vertical-align: bottom; font-size: 10pt; text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_7e3d2ed42fd44208b805e0fa811d6c66" contextRef="c20250814to20250814" format="ixt-sec:stateprovnameen">Maryland</ix:nonNumeric><br/>
          </td>

    <td style="width: 34%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_b7cba9d8b3bf47adbd14e58bfe6ae305" contextRef="c20250814to20250814">001-36181</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 33%; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_0fc09458aa3f43ad8ea4612948faecb1" contextRef="c20250814to20250814">46-3999490</ix:nonNumeric><br/>
          </td>

  </tr>

  <tr>

    <td style="width: 33%; vertical-align: bottom;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(State or other jurisdiction of incorporation)</div>
          </td>

    <td style="width: 34%; vertical-align: bottom;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Commission File Number)</div>
          </td>

    <td style="width: 33%; vertical-align: bottom;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(IRS Employer Identification No.)</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 49%; vertical-align: bottom; text-align: center;"><span style="font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_fe7f390b403d45c3b575298b9ce890c0" contextRef="c20250814to20250814">905 Calle Amanecer, Suite 300,</ix:nonNumeric></span>
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_f3da7cf52af74c9ab11d402b0f7b0675" contextRef="c20250814to20250814">San Clemente</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_7c6465b72e504c23ad86c4c8bfc42d15" contextRef="c20250814to20250814">CA</ix:nonNumeric></div>
          </td>

    <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>

    <td style="width: 49%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_6a15c0b075e74694ad8c49cac6888e7c" contextRef="c20250814to20250814">92673</ix:nonNumeric><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(Address of principal executive offices)</div>
          </td>

    <td style="width: 2%; vertical-align: bottom; font-size: 10pt;" colspan="1">&#160;</td>

    <td style="width: 49%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(Zip Code)</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Registrant&#8217;s telephone number, including area code (<ix:nonNumeric name="dei:CityAreaCode" id="Fact_525a64eed0ff4f7fa8697784555573c1" contextRef="c20250814to20250814">949</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_c0f2d723d2eb41d9a5ebd8f46c9c3267" contextRef="c20250814to20250814">542-3130</ix:nonNumeric></div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; font-size: 10pt;">
      <hr style="height: 2px; width: 20%; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
      following provisions (see General Instruction A.2 below):</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_c5fb312bda6f40859e40de61132efc0f" contextRef="c20250814to20250814" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_adc0f3a7ea20405098d1b19ef7bda725" contextRef="c20250814to20250814" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_5358cc7fb39d49eb930209b18f2bf848" contextRef="c20250814to20250814" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_e771263c17144f3eb54b77448767840a" contextRef="c20250814to20250814" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 37.49%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><span style="text-decoration: underline;">Title of each class</span></div>
          </td>

    <td style="width: 20.21%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><span style="text-decoration: underline;">Trading Symbol(s)</span></div>
          </td>

    <td style="width: 42.3%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><span style="text-decoration: underline;">Name of each exchange on which registered</span></div>
          </td>

  </tr>

  <tr>

    <td style="width: 37.49%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_c079aa9dac6f4139b8505c9aa1e3b6fb" contextRef="c20250814to20250814">Common Stock, par value $0.01 per share</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 20.21%; vertical-align: top; font-size: 10pt; text-align: center;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_6c7e4c887e8d49eeaa404d403832b43e" contextRef="c20250814to20250814">CTRE</ix:nonNumeric><br/>
          </td>

    <td style="width: 42.3%; vertical-align: top; font-size: 10pt; text-align: center;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_fa63714a2dab4acbb9adcc12580e10de" contextRef="c20250814to20250814" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric><br/>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Sec. 230.405 of this
      chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Sec. 240.12b-2 of this chapter).</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_4c16e78ec09746328ba07669746f3346" contextRef="c20250814to20250814" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
      revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act:&#160; &#9744;</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="font-size: 10pt;">
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/></div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    </div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 8.01</div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Other Events</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">On August 12, 2025, CareTrust REIT, Inc. (the &#8220;Company&#8221;) and its operating partnership, CTR Partnership, L.P., entered into an
      underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with J.P. Morgan Securities LLC, BofA Securities, Inc. and RBC Capital Markets, LLC, on behalf of themselves and as representatives of the several underwriters named in Schedule I thereto
      (collectively, the &#8220;Underwriters&#8221;), pursuant to which the Company agreed to sell, and the Underwriters agreed to purchase, 20,000,000 shares (the &#8220;Firm Shares&#8221;) of the Company&#8217;s common stock, par value $0.01 per share (the &#8220;Common Stock&#8221;), at an
      initial price to the public of $32.00 per share (the &#8220;Purchase Price&#8221;). The Company also granted the Underwriters a 30-day option to purchase up to an additional 3,000,000 shares of Common Stock (the &#8220;Option Shares&#8221; and, together with the Firm
      Shares, the &#8220;Shares&#8221;) at the Purchase Price. The Underwriters exercised their option to purchase the Option Shares in full on August 13, 2025.</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The Company issued and delivered the Shares on August 14, 2025.</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The offering of the Shares was made pursuant to the Company&#8217;s automatic shelf registration statement on Form S-3 (File No. 333-269998),
      filed by the Company with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on February 24, 2023, a base prospectus, dated February 24 2023, included as part of the registration statement, and the final prospectus supplement, dated August 12, 2025,
      filed by the Company with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended, on August 13, 2025.</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The Company is filing as Exhibit 5.1 to this Current Report on Form 8-K an opinion of DLA Piper LLP (US) regarding certain matters of
      Maryland law, including the validity of the Shares issued and sold in the offering.</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The foregoing summary of the Underwriting Agreement is qualified in its entirety by reference to the full text of the Underwriting
      Agreement, a copy of which is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01</div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Financial Statements and Exhibits</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(d) Exhibits.</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 7.49%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; white-space: nowrap;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Exhibit</div>
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">No.</div>
          </td>

    <td style="width: 1%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 92.45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Description</div>
          </td>

  </tr>

  <tr>

    <td style="width: 7.49%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';"><a href="ef20053958_ex1-1.htm">1.1</a></div>
          </td>

    <td style="width: 1%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 92.45%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Underwriting Agreement, dated August 12, 2025, by and among CareTrust REIT, Inc., CTR Partnership, L.P. and J.P. Morgan Securities LLC, BofA Securities, Inc. and RBC Capital
              Markets, LLC, on behalf of themselves and as representatives of the several underwriters named in Schedule I thereto.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 7.49%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';"><a href="ef20053958_ex5-1.htm">5.1</a></div>
          </td>

    <td style="width: 1%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 92.45%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Opinion of DLA Piper LLP (US).</div>
          </td>

  </tr>

  <tr>

    <td style="width: 7.49%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';"><a href="ef20053958_ex5-1.htm">23.1</a></div>
          </td>

    <td style="width: 1%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 92.45%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Consent of DLA Piper LLP (US) (included in Exhibit 5.1).</div>
          </td>

  </tr>

  <tr>

    <td style="width: 7.49%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">104</div>
          </td>

    <td style="width: 1%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 92.45%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Cover Page Interactive Data File (embedded within the inline XBRL document).</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    </div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SIGNATURES</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
      behalf by the undersigned hereunto duly authorized.</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="vertical-align: bottom; font-size: 10pt;" colspan="2">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">CARETRUST REIT, INC.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="vertical-align: bottom; font-size: 10pt;" colspan="2">&#160;</td>

  </tr>

  <tr>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 10%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">By:</div>
          </td>

    <td style="width: 89%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">/s/ William M. Wagner</div>
          </td>

  </tr>

  <tr>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 10%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Name:</div>
          </td>

    <td style="width: 89%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">William M. Wagner</div>
          </td>

  </tr>

  <tr>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 10%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Title:</div>
          </td>

    <td style="width: 89%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Chief Financial Officer and Treasurer</div>
          </td>

  </tr>

  <tr>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;" rowspan="1">&#160;</td>

    <td style="width: 10%; vertical-align: bottom; font-size: 10pt;" rowspan="1">&#160;</td>

    <td style="width: 89%; vertical-align: bottom; font-size: 10pt;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;" rowspan="1" colspan="2">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Date:</div>
          </td>

    <td style="width: 89%; vertical-align: bottom; font-size: 10pt;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;" rowspan="1" colspan="2">
            <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">August 14, 2025</div>
          </td>

    <td style="width: 89%; vertical-align: bottom; font-size: 10pt;" rowspan="1">&#160;</td>

  </tr>


</table>
<div><br/>

    <br/></div>

    <div style="font-size: 10pt;">
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

  </div>

  <div><span style="font-size: 10pt;"> </span></div>

</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ef20053958_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solution Inc.
         Document created using Broadridge PROfile 25.7.1.5324
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-size: 10pt;"> </font>
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a name="z_mps202894580000000000000004054000000000"></a></div>
    <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> Exhibit 1.1<br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CareTrust REIT, Inc.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">20,000,000 Shares</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Common Stock, par value $0.01 per share</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>UNDERWRITING AGREEMENT</u></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: right; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">August 12, 2025</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">J.P. Morgan Securities LLC</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">BofA Securities, Inc.</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">RBC Capital Markets, LLC</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">As Representatives of the several Underwriters</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">c/o J.P. Morgan Securities LLC</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">383 Madison Avenue</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">New York, New York 10179</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Ladies and Gentlemen:</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">CareTrust REIT, Inc., a Maryland corporation (&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">CareTrust</font>&#8221;),

      and CTR Partnership, L.P., a Delaware limited partnership (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Operating Partnership</font>&#8221;), confirm their agreement with the several underwriters named in <font style="font-family: 'Times New Roman';"><u>Schedule I</u></font> hereto (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Underwriters</font>&#8221;), for whom J.P. Morgan Securities LLC, BofA Securities, Inc. and
      RBC Capital Markets, LLC are acting as representatives (collectively, in such capacity, the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Representatives</font>&#8221;), with respect to the issuance and sale by
      CareTrust and the purchase by the Underwriters, acting severally and not jointly, of an aggregate of 20,000,000 shares (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Firm Shares</font>&#8221;) of common stock,
      par value $0.01 per share, of CareTrust (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Common Stock</font>&#8221;) from CareTrust.&#160; In addition, the Underwriters have been granted an option to purchase up to an
      aggregate of 3,000,000 additional shares of Common Stock (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Optional Shares</font>&#8221;), if and to the extent that the Representatives, as managers of the offering,
      shall have determined to exercise, on behalf of the Underwriters, the right to purchase such shares of Common Stock granted to the Underwriters, as provided in <font style="font-family: 'Times New Roman';"><u>Section 2</u></font> hereof.&#160; The Firm
      Shares and the Optional Shares are hereinafter collectively referred to as the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Shares</font>.&#8221;</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;">Representations and Warranties of CareTrust and the Operating Partnership</font>.&#160; CareTrust and the Operating Partnership each severally represents and warrants to, and agrees with, each of the Underwriters that:</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">CareTrust has prepared and filed with
          the Securities and Exchange Commission (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Commission</font>&#8221;) an &#8220;automatic shelf registration statement&#8221; as defined in Rule 405 (&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Rule 405</font>&#8221;) under the Securities Act of 1933, as amended, and the rules and regulations of the Commission promulgated thereunder (collectively, the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Securities Act</font>&#8221;), on Form S-3 (Registration No. 333-269998), including a form of prospectus (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Base Prospectus</font>&#8221;), to be used in connection with the public offering and sale of the Common Stock.&#160; Such registration statement, including the financial statements, exhibits and schedules thereto, at the time of effectiveness
          pursuant to Rule 430A or Rule 430B under the Securities Act, including all information and documents incorporated or deemed incorporated by reference therein under the Securities Act or the Securities Exchange Act of 1934, as amended, and the
          rules and regulations promulgated thereunder (collectively, the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Exchange Act</font>&#8221;), is herein called the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Registration Statement</font>.&#8221; The preliminary prospectus supplement dated August 12, 2025 describing the Shares and the offering thereof, together with the Base Prospectus, is herein called the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Preliminary Prospectus</font>,&#8221; and the Preliminary Prospectus and any other preliminary prospectus supplement to the Base Prospectus that describes the Shares and
          the offering thereof that is used prior to the filing of the Prospectus (as defined below), together with the Base Prospectus, is called a &#8220;preliminary prospectus.&#8221; The Preliminary Prospectus, including the Base Prospectus, relating to the Shares
          that was included in the Registration Statement immediately prior to the Applicable Time (as defined below) is herein called the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Time of Sale Prospectus</font>.&#8221;

          As used herein, the term &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Prospectus</font>&#8221; shall mean the final prospectus supplement to the Base Prospectus that describes the Shares and the offering
          thereof, together with the Base Prospectus, in the form first used by the Underwriters to confirm sales of the Shares or in the form first made available to the Underwriters by CareTrust to meet the requests of purchasers pursuant to Rule 173
          under the Securities Act.&#160; Any &#8220;issuer free writing prospectus&#8221; (as defined in Rule 433 of the Securities Act) is herein called an &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Issuer Free Writing
            Prospectus</font>.&#8221; For purposes of this Agreement, all references to the Registration Statement, any preliminary prospectus, the Preliminary Prospectus, the Time of Sale Prospectus, the Prospectus or any amendment or supplement to any of the
          foregoing shall be deemed to refer to and include the copy filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval system (&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">EDGAR</font>&#8221;).&#160;

          For purposes of this Agreement, the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Applicable Time</font>&#8221; is 6:30 p.m. (Eastern time) on August 12, 2025.&#160; As used herein, the terms &#8220;Registration Statement,&#8221;
          &#8220;preliminary prospectus,&#8221; &#8220;Preliminary Prospectus,&#8221; &#8220;Time of Sale Prospectus&#8221; and &#8220;Prospectus&#8221; shall include the documents incorporated and deemed to be incorporated by reference therein.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">All references in this Agreement to financial statements and schedules and other information which is &#8220;contained,&#8221; &#8220;included&#8221; or &#8220;stated&#8221; in, or &#8220;part
      of&#8221; or other references of like import with respect to the Registration Statement, any preliminary prospectus, the Preliminary Prospectus, the Time of Sale Prospectus or the Prospectus shall be deemed to mean and include all such financial statements
      and schedules and other information that is or is deemed to be incorporated by reference in the Registration Statement, any preliminary prospectus, the Preliminary Prospectus, the Time of Sale Prospectus or the Prospectus, as the case may be&#894; and all
      references in this Agreement to amendments or supplements to the Registration Statement, any preliminary prospectus, the Preliminary Prospectus, the Time of Sale Prospectus or the Prospectus shall be deemed to mean and include the filing of any
      document under the Exchange Act that is incorporated by reference in the Registration Statement, any preliminary prospectus, the Preliminary Prospectus, the Time of Sale Prospectus or the Prospectus, as the case may be.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-family: 'Times New Roman';">(i) At the time of filing the
          Registration Statement, (ii) at the earliest time that CareTrust or another offering participant made a <font style="font-family: 'Times New Roman'; font-style: italic;">bona fide </font>offer (within the meaning of Rule 164 under the
          Securities Act) of the Shares and (iii) at the date hereof, CareTrust was not and is not an &#8220;ineligible issuer&#8221; in connection with the offering of the Shares pursuant to Rules 164, 405 and 433 under the Securities Act.&#160; No order preventing or
          suspending the use of any preliminary prospectus, the Time of Sale Prospectus or any Issuer Free Writing Prospectus has been issued by the Commission.&#160; Each preliminary prospectus, the Time of Sale Prospectus and the Prospectus, at the time of
          filing thereof, complied, and any further amendments or supplements thereto will comply, in all material respects, with the Securities Act, and did not contain an untrue statement of a material fact or omit to state any material fact necessary in
          order to make the statements therein, in the light of the circumstances under which they were made, not misleading.&#160; The representation and warranty set forth in the immediately preceding sentence does not apply to statements or omissions made in
          reliance upon and in conformity with written information relating to any Underwriter furnished to CareTrust in writing by the Representatives expressly for inclusion therein, which information consists solely of the information set forth in <font style="font-family: 'Times New Roman';"><u>Section 7(b)</u></font> hereof.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-family: 'Times New Roman';">The Time of Sale Prospectus, as
          supplemented by those Issuer Free Writing Prospectuses and other materials and information listed in <font style="font-family: 'Times New Roman';"><u>Schedule II</u></font> hereto, taken together (collectively, the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Disclosure Package</font>&#8221;) as of the Applicable Time, complied, in all material respects, with the Securities Act, and did not include any untrue statement of a material fact or omit
          to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.&#160; Each Issuer Free Writing Prospectus listed on <font style="font-family: 'Times New Roman';"><u>Schedule II</u></font> or <font style="font-family: 'Times New Roman';"><u>Schedule III</u></font> hereto does not conflict with the information contained in the Registration Statement, the Time of Sale Prospectus or the
          Prospectus, and each such Issuer Free Writing Prospectus, as supplemented by and taken together with the Disclosure Package as of the Applicable Time, did not include any untrue statement of a material fact or omit to state any material fact
          necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.&#160; The representations and warranties set forth in the two immediately preceding sentences do not apply to statements
          or omissions made in reliance upon and in conformity with written information relating to any Underwriter furnished to CareTrust in writing by the Representatives expressly for inclusion therein, which information consists solely of the
          information set forth in <font style="font-family: 'Times New Roman';"><u>Section 7(b)</u></font> hereof.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">The Registration Statement and any
          post-effective amendment thereto have become effective under the Securities Act.&#160; CareTrust has responded to all requests, if any, of the Commission for additional or supplemental information.&#160; No stop order suspending the effectiveness of the
          Registration Statement is in effect and no proceedings for such purpose or pursuant to Section 8A of the Securities Act have been instituted or are pending or, to CareTrust&#8217;s best knowledge, are contemplated or threatened by the Commission.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">The Registration Statement complies,
          and the Prospectus and any further amendments or supplements thereto will comply, in each case in all material respects, with the Securities Act.&#160; The Registration Statement, and any post-effective amendment thereto, does not and will not
          contain, as of the applicable effective date, any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.&#160; The Prospectus, and any supplements
          thereto, as of its date or the date of such supplement and on each Delivery Date (as defined below), does not and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements
          therein, in the light of the circumstances under which they were made, not misleading.&#160; The representations and warranties set forth in the two immediately preceding sentences do not apply to statements or omissions made in reliance upon and in
          conformity with written information furnished to CareTrust by an Underwriter expressly for inclusion therein, which information consists solely of the information set forth in <font style="font-family: 'Times New Roman';"><u>Section 7(b)</u></font>
          hereof.&#160; There are no contracts or other documents required to be described in the Time of Sale Prospectus or the Prospectus or filed as exhibits to the Registration Statement that have not been described or filed as required.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">3</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(f)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">The Time of Sale Prospectus was, and
          the Prospectus delivered to the Underwriters for use in connection with this offering will be, identical to the versions of the Time of Sale Prospectus and Prospectus created to be transmitted to the Commission for filing via EDGAR, except to the
          extent permitted by Regulation S-T.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(g)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">At the time the Registration Statement
          originally became effective, CareTrust was permitted to use Form S-3 under the Securities Act.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(h)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">(i) At the time of filing the
          Registration Statement, (ii) at the time of the most recent amendment thereto for the purposes of complying with Section 10(a)(3) of the Securities Act (whether such amendment was by post-effective amendment, incorporated report filed pursuant to
          Section 13 or 15(d) of the Exchange Act or form of prospectus), (iii) at the time CareTrust made any offer relating to the Shares in reliance on the exemption of Rule 163 of the Securities Act and (iv) at the date hereof, CareTrust was and is a
          &#8220;well-known seasoned issuer&#8221; as defined in Rule 405.&#160; The Shares, since their registration on the Registration Statement, have been and remain eligible for registration by CareTrust on a Rule 405 &#8220;automatic shelf registration statement.&#8221;
          CareTrust has not received from the Commission any notice pursuant to Rule 401(g)(2) of the Securities Act objecting to the use of the Registration Statement.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(i)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">The documents incorporated by reference
          or deemed to be incorporated by reference in the Disclosure Package and the Prospectus, when they were filed with the Commission, conformed in all material respects to the requirements of the Exchange Act, and did not contain an untrue statement
          of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading&#894; and any further documents so filed and incorporated by reference
          or deemed to be incorporated by reference in the Disclosure Package or the Prospectus or any supplement thereto, when such documents are filed with the Commission, will conform in all material respects to the requirements of the Exchange Act and
          will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(j)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Except as otherwise disclosed in the
          Registration Statement, the Disclosure Package and the Prospectus, since the respective dates as of which information is given in the Registration Statement, the Disclosure Package and the Prospectus (in each case exclusive of any amendments or
          supplements thereto subsequent to the date of this Agreement), (i) there has been no material adverse change or any development that could reasonably be expected to result in a material adverse change, in the condition (financial or other),
          results of operations, business, properties, management or prospects of CareTrust, the Operating Partnership or the direct and indirect subsidiaries (as defined in Rule 1-02(x) of Regulation S-X) of CareTrust and/or the Operating Partnership (the
          &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Subsidiaries</font>&#8221;), taken as a whole (in any such case, a &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Material
            Adverse Effect</font>&#8221;)&#894; (ii) none of CareTrust, the Operating Partnership or any of the Subsidiaries has incurred any liability or obligation, direct or contingent, or entered into any transaction or agreement that, individually or in the
          aggregate, is material with respect to CareTrust, the Operating Partnership and the Subsidiaries taken as a whole, and none of CareTrust, the Operating Partnership and the Subsidiaries has sustained any loss or interference with its business or
          operations from fire, explosion, flood, earthquake or other natural disaster or calamity, whether or not covered by insurance, or from any labor dispute or disturbance or court or governmental action, order or decree which could reasonably be
          expected, individually or in the aggregate, to result in a Material Adverse Effect&#894; and (iii) there has been no distribution of any kind declared, paid or made by the Operating Partnership on any partnership interest, other than distributions
          paid to CareTrust or CareTrust GP, LLC.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">4</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(k)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-family: 'Times New Roman';">Each of CareTrust, the Operating
          Partnership and the Subsidiaries has been duly incorporated or organized, as applicable, and is validly existing as a corporation, limited partnership or limited liability company, as the case may be, in good standing under the laws of the state
          of its jurisdiction of incorporation or organization, as applicable, and has the power and authority to own, lease and operate its properties and to conduct its business as described in the Disclosure Package and the Prospectus, except where the
          failure to be in good standing or have such power and authority would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.&#160; Each of CareTrust, the Operating Partnership and the Subsidiaries is duly
          qualified as a foreign corporation, limited partnership or limited liability company, as the case may be, to transact business and is in good standing in each jurisdiction in which such qualification is required, whether by reason of the
          ownership or leasing of property or the conduct of business, except where the failure to so qualify or to be in good standing would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.&#160; CareTrust
          owns 100% of CareTrust GP, LLC, which is the sole general partner of the Operating Partnership.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(l)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-family: 'Times New Roman';">All of the issued and outstanding
          shares of each of CareTrust and the Subsidiaries that is a corporation, all of the issued and outstanding partnership interests of each of the Operating Partnership and the Subsidiaries that is a limited partnership and all of the issued and
          outstanding limited liability company interests, membership interests or other similar interests of each of the Subsidiaries that is a limited liability company have been duly authorized and validly issued, are (except in the case of general
          partnership interests and limited liability company interests) fully paid and non-assessable and were issued in compliance with all applicable state and federal securities and &#8220;Blue Sky&#8221; laws, and are owned by CareTrust, directly or through
          subsidiaries, free and clear of any lien, security interest, mortgage, pledge, encumbrance or claim (each, a &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Lien</font>&#8221;), except as otherwise disclosed in the
          Disclosure Package and the Prospectus.&#160; None of the issued and outstanding shares of capital stock of any of CareTrust and the Subsidiaries that is a corporation, none of the issued and outstanding partnership interests of any of the Operating
          Partnership and the Subsidiaries that is a limited or general partnership, and none of the issued and outstanding limited liability company interests, membership interests or other similar interests of any Subsidiary that is a limited liability
          company was issued in violation of any preemptive rights, rights of first refusal or other similar rights of any security holder of such entity or any other person.&#160; Except with respect to preferred equity investments in joint ventures as
          disclosed in the Disclosure Package and the Prospectus, each of CareTrust and the Operating Partnership does not own or control, directly or indirectly, any corporation, association or other entity other than the Subsidiaries&#894; the Operating
          Partnership is a Subsidiary of CareTrust.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(m)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">This Agreement has been duly
          authorized, executed and delivered by each of CareTrust and the Operating Partnership.&#160; Each of CareTrust and the Operating Partnership has full right, power and authority to execute, deliver and perform its obligations under this Agreement.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">5</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(n)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-family: 'Times New Roman';">CareTrust has an authorized
          capitalization as set forth in the Disclosure Package and the Prospectus.&#160; The shares of issued and outstanding capital stock of CareTrust have been duly authorized and validly issued and are fully paid and non-assessable and were issued in
          compliance with all applicable state and federal securities and &#8220;Blue Sky&#8221; laws.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(o)</font><font style="font-size: 10pt;">&#160;&#160;&#160; &#160;&#160; &#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">The Common Stock conforms in all
          material respects to the statements relating thereto contained in the Registration Statement, the Disclosure Package and the Prospectus&#894; the Shares have been duly authorized and, when issued and delivered in accordance with the terms of this
          Agreement, will be validly issued, fully paid and nonassessable, and conform to the description thereof contained in the Disclosure Package and the Prospectus.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(p)</font><font style="font-size: 10pt;">&#160;&#160; &#160; &#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">Other than as described in the
          Disclosure Package and the Prospectus, there are no contracts, agreements or understandings between CareTrust and any person granting such person the right to require CareTrust to file a registration statement under the Securities Act with
          respect to any shares of Common Stock or any other securities of CareTrust owned or to be owned by such person or to require CareTrust to include such Common Stock or other securities in the Registration Statement.&#160; To the extent any person has
          such registration or offer similar rights, such rights have been waived with respect to the registration of securities in connection with the Registration Statement.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(q)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">No consent, approval, authorization,
          or order of, or filing or registration with, any governmental agency or body or any court is required for the consummation of the transactions contemplated by this Agreement, except (i) such as have been made or obtained under the Securities Act,
          or (ii) the consents, approvals, authorizations, registrations or qualifications as may be required by state securities or &#8220;Blue Sky&#8221; laws or by the Financial Industry Regulatory Authority (&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">FINRA</font>&#8221;).</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(r)</font><font style="font-size: 10pt;">&#160;&#160;&#160; &#160;&#160; &#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">None of CareTrust, the Operating
          Partnership or the Subsidiaries is (i) in violation of its (a) in the case of a corporation, charter and by-laws&#894; (b) in the case of a limited or general partnership, partnership certificate, certificate of formation or similar organizational
          document and partnership agreement&#894; (c) in the case of a limited liability company, articles of organization, certificate of formation or similar organizational documents and operating agreement, limited liability company agreement, membership
          agreement or other similar agreement&#894; (d) in the case of a trust, certificate of trust, certificate of formation or similar organizational document and trust agreement or other similar agreement&#894; and (e) in the case of any other entity, the
          organizational and governing documents of such entity, (ii) in violation of any applicable law, statute, rule, regulation, judgment, order, writ or decree of any government, government instrumentality or court, domestic or foreign, having
          jurisdiction over CareTrust, the Operating Partnership or the Subsidiaries or any of their respective assets, properties or operations or (iii) in breach or default (or with or without the giving of notice or the passage of time or both, would be
          in breach or default) in the performance or observance of any obligation, agreement, covenant or condition contained in any contracts, indentures, mortgages, deeds of trust, loan or credit agreements, bonds, notes, debentures, evidences of
          indebtedness, swap agreements, leases or other instruments or agreements to which it is a party or by which it is bound or to which any of its property or assets are subject (collectively, &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Company Documents</font>&#8221;), except, in the cases of clauses (ii) or (iii) for such violations, breaches or defaults that would not, individually or in the aggregate, reasonably be expected to result in a
          Material Adverse Effect.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">6</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(s)</font><font style="font-size: 10pt;">&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman';">The execution, delivery and
          performance by CareTrust and the Operating Partnership of this Agreement and the consummation by CareTrust, the Operating Partnership and the Subsidiaries of the issuance and sale of the Shares and the use of the proceeds from the sale of the
          Shares as described in the Disclosure Package and the Prospectus under the caption &#8220;Use of Proceeds&#8221; and compliance by CareTrust and the Operating Partnership with their respective obligations under this Agreement, (i) do not and will not,
          whether with or without the giving of notice or passage of time or both, conflict with or constitute a breach of, or default, event or condition which gives any person the right, either immediately or with notice or passage of time or both, to
          terminate or limit (in whole or in part) any Company Documents or any rights of CareTrust, the Operating Partnership or any Subsidiary thereunder including, without limitation, upon the occurrence of a change of control of any of CareTrust, the
          Operating Partnership or any Subsidiary or other similar events (each, a &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Termination Event</font>&#8221;) or event or condition which, either immediately or with
          notice or passage of time or both, (a) gives the holder of any bond, note, debenture or other evidence of indebtedness (or any person acting on such holder&#8217;s behalf) the right to require the repurchase, redemption or repayment of all or a portion
          of such indebtedness by CareTrust, the Operating Partnership or any Subsidiary, or (b) gives any counterparty (or any person acting on such counterparty&#8217;s behalf) under any swap agreement, hedging agreement or similar agreement or instrument to
          which CareTrust, the Operating Partnership or any Subsidiary is a party the right to liquidate or accelerate the payment obligations or designate an early termination date under such agreement or instrument, as the case may be (each, a &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Repayment Event</font>&#8221;) under, or result in the creation or imposition of any Lien upon any property or assets of CareTrust, the Operating Partnership or any
          Subsidiary pursuant to, any Company Documents, except for any such conflict, breach, default, Termination Event, Repayment Event or Lien that would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse
          Effect, and (ii) will not result in any violation of (a) the provisions of the organizational documents of CareTrust, the Operating Partnership or any Subsidiary or (b) (assuming compliance with any applicable securities or &#8220;Blue Sky&#8221; laws of the
          jurisdictions in which the Shares are offered by the Underwriters and assuming that the Underwriters comply with the agreements contained herein) law, statute, rule, regulation, judgment, order, writ or decree of any government, government
          instrumentality or court, domestic or foreign, having jurisdiction over CareTrust, the Operating Partnership or any Subsidiary or any of their respective assets, properties or operations.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">7</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(t)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">Except as otherwise disclosed in the
          Disclosure Package and the Prospectus, (i) CareTrust, the Operating Partnership and the Subsidiaries have good and marketable title (in fee simple) to all assets described in the Disclosure Package and the Prospectus as being owned by them, and
          none of CareTrust, the Operating Partnership or any Subsidiary has received notice of any claim that has been or may be asserted by anyone adverse to the rights of CareTrust, the Operating Partnership or any Subsidiary with respect to such assets
          or affecting or questioning the rights of any of CareTrust, the Operating Partnership or any Subsidiary to the continued ownership, possession or occupancy of such assets, except for such claims that would not, individually or in the aggregate,
          reasonably be expected to have a Material Adverse Effect&#894; (ii) all Liens or restrictions on or affecting the assets CareTrust, the Operating Partnership or any Subsidiary that are required to be disclosed in the Disclosure Package or the
          Prospectus are disclosed therein, and all such Liens or restrictions which are not disclosed in the Disclosure Package and the Prospectus could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect&#894; (iii)
          no person or entity has an option or right of first refusal or any other right to purchase any of the assets leased to or owned by CareTrust, the Operating Partnership or any Subsidiary, except where any such option or right would not,
          individually or in the aggregate, have a Material Adverse Effect&#894; (iv) each of the assets leased to or owned by CareTrust, the Operating Partnership or any Subsidiary has access to public rights of way, either directly or through insured
          easements, except where the failure to have such access would not, individually or in the aggregate, have a Material Adverse Effect&#894; (v) each of the assets controlled by CareTrust, the Operating Partnership or any Subsidiary is served by all
          public utilities necessary for the current operations on such property sufficient for such operations, except where the failure to have such public utilities would not, individually or in the aggregate, reasonably be expected to have a Material
          Adverse Effect&#894; (vi) the assets leased to or owned by CareTrust, the Operating Partnership or any Subsidiary comply, in all material respects, with all applicable codes and zoning and subdivision laws and regulations or the use thereof is
          permitted as a legal non-conforming use&#894; (vii) all of the leases under which CareTrust, the Operating Partnership or any Subsidiary leases (as lessee) any real property or improvements or any equipment relating to such real property or
          improvements are in full force and effect, except where the failure to be in full force and effect would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, and none of CareTrust, the Operating
          Partnership or any Subsidiary is in default in the payment of any amounts due under any such leases or otherwise in default thereunder and none of CareTrust, the Operating Partnership or any Subsidiary knows of any event that, with the passage of
          time or the giving of notice or both, would constitute a default under any such lease, except such defaults that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect&#894; (viii) there is no pending or,
          to the knowledge of CareTrust, the Operating Partnership or any Subsidiary, threatened condemnation, zoning change, or other proceeding or action that could in any manner affect the size of, use of, improvements on, construction on or access to
          any asset leased to or owned by CareTrust, the Operating Partnership or any Subsidiary, except such proceedings or actions that, either individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect&#894; and (ix)
          all of the leases under which CareTrust, the Operating Partnership or any Subsidiary leases (as lessor) any real property or improvements (whether directly or indirectly through partnerships, joint ventures or otherwise) are in full force and
          effect, except where the failure to be in full force and effect would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, and none of CareTrust, the Operating Partnership or any Subsidiary nor any
          lessee of any of the real property or improvements of CareTrust, the Operating Partnership or any Subsidiary is in default in the payment of any amounts due under any such leases or otherwise in default thereunder, and none of CareTrust, the
          Operating Partnership or any Subsidiary knows of an event which, with the passage of time or the giving of notice or both, would constitute such a default under any of such leases, except such defaults as would not, individually or in the
          aggregate, reasonably be expected to have a Material Adverse Effect.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(u)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">CareTrust, the Operating Partnership and
          the Subsidiaries possess such permits, licenses, approvals, accreditations, certifications, registrations, certificates, consents and other authorizations (collectively, &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Governmental Licenses</font>&#8221;) issued by the appropriate federal, state, local or foreign regulatory agencies or bodies to the extent required to conduct the business to be operated by them as described in the Disclosure Package and
          the Prospectus, except where the failure to possess such Governmental Licenses would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.&#160; CareTrust, the Operating Partnership and the Subsidiaries
          are in compliance with the terms and conditions of all such Governmental Licenses, except where the failure so to comply would not, individually or in the aggregate, result in a Material Adverse Effect.&#160; None of CareTrust, the Operating
          Partnership or any Subsidiary has received any written notice of proceedings relating to the revocation or modification of any such Governmental Licenses, except where such revocation or modification would not, individually or in the aggregate,
          reasonably be expected to result in a Material Adverse Effect.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">8</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(v)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">The statements made in or
          incorporated by reference into the Disclosure Package and the Prospectus, insofar as they purport to constitute summaries of the terms of statutes, rules or regulations, legal or governmental proceedings or contracts and other documents,
          constitute accurate summaries of the terms of such statutes, rules and regulations, legal and governmental proceedings and contracts and other documents in all material respects.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(w)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">There is no action, suit, proceeding,
          inquiry or investigation before or brought by any court or governmental agency or body, domestic or foreign, now pending, or, to the knowledge of CareTrust, the Operating Partnership or any of the Subsidiaries, threatened, against or affecting
          CareTrust, the Operating Partnership or any of the Subsidiaries (other than as disclosed in the Disclosure Package or the Prospectus) which could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(x)</font><font style="font-size: 10pt;">&#160;&#160;&#160; &#160; &#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">No labor dispute with the employees
          of any of CareTrust, the Operating Partnership or any Subsidiary exists or, to the knowledge of CareTrust, the Operating Partnership or any Subsidiary, is imminent, in each case, which could reasonably be expected, individually or in the
          aggregate, to result in a Material Adverse Effect or to materially and adversely affect the consummation of the transactions contemplated in this Agreement or the performance by any of CareTrust or the Operating Partnership of its obligations
          under this Agreement.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(y)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman';">None of the following events has
          occurred or exists: (i) a failure to fulfill the obligations, if any, under the minimum funding standards of Section 302 of the Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations
          thereunder (collectively, &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">ERISA</font>&#8221;) with respect to a Plan determined without regard to any waiver of such obligations or extension of any amortization
          period&#894; (ii) an audit or investigation by the Internal Revenue Service, the U.S. Department of Labor, the Pension Benefit Guaranty Corporation or any other federal, state or foreign governmental or regulatory agency with respect to the
          employment, compensation or benefits of employees of CareTrust, the Operating Partnership or any Subsidiary that could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect&#894; or (iii) any breach or
          termination of any contractual obligation, or any violation of law or applicable qualification standards, with respect to the employment, compensation or benefits of employees of CareTrust, the Operating Partnership or any Subsidiary or with
          respect to a Plan that could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect.&#160; None of the following events has occurred or is reasonably likely to occur: (i) a material increase in the aggregate
          amount of contributions required to be made to all Plans in the current fiscal year of CareTrust, the Operating Partnership and any Subsidiary compared to the amount of such contributions made in CareTrust&#8217;s most recently completed fiscal year&#894;
          (ii) a material increase in the &#8220;accumulated post-retirement benefit obligations&#8221; (within the meaning of Statement of Financial Accounting Standards 106) of CareTrust, the Operating Partnership and the Subsidiaries in the current fiscal year of
          CareTrust, the Operating Partnership and any Subsidiary compared to the amount of such obligations in CareTrust&#8217;s most recently completed fiscal year&#894; (iii) any event or condition giving rise to a liability under Title IV of ERISA with respect to
          a Plan that could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect&#894; or (iv) the filing of a claim by one or more employees or former employees of CareTrust, the Operating Partnership or any
          Subsidiary related to its or their employment that could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect.&#160; For purposes of this paragraph, the term &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Plan</font>&#8221; means a plan (within the meaning of Section 3(3) of ERISA) with respect to which CareTrust, the Operating Partnership or any Subsidiary may have any liability.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">9</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(z)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-family: 'Times New Roman';">(i) CareTrust, the Operating
          Partnership and the Subsidiaries own and possess or have valid and enforceable licenses to use, all patents, patent rights, patent applications, licenses, copyrights, inventions, know how (including trade secrets and other unpatented and/or
          unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks, trade names, service names, software, internet addresses, domain names and other intellectual property (collectively, &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Intellectual Property</font>&#8221;) that are described in the Disclosure Package or the Prospectus or that are necessary for the conduct of their respective businesses as
          described in the Disclosure Package and the Prospectus&#894; (ii) none of CareTrust, the Operating Partnership or any Subsidiary has received any notice or is otherwise aware of any infringement of or conflict with rights of others with respect to any
          Intellectual Property or of any facts or circumstances which would render any Intellectual Property invalid or inadequate to protect the interests of CareTrust, the Operating Partnership or any Subsidiary therein&#894; (iii) there are no third parties
          who have or, to the knowledge of CareTrust, the Operating Partnership or any Subsidiary, will be able to establish rights to any Intellectual Property of CareTrust, the Operating Partnership or any Subsidiary and (iv) there is no pending or, to
          the knowledge of CareTrust, the Operating Partnership or any Subsidiary, threatened action, suit, proceeding or claim by others challenging CareTrust&#8217;s, the Operating Partnership&#8217;s or any Subsidiary&#8217;s rights in or to any such Intellectual
          Property, except in the case of each of clauses (i)-(iv) as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">10</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(aa)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-family: 'Times New Roman';">Except as otherwise disclosed in the
          Disclosure Package and the Prospectus: (i) to the best knowledge of CareTrust, the assets controlled by CareTrust, the Operating Partnership and the Subsidiaries, including, without limitation, the Environment (as defined below) associated with
          such assets, is free of any Contaminant (as defined below), except such Contaminants which, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect&#894; (ii) none of CareTrust, the Operating Partnership or
          any Subsidiary has caused any Release (as defined below) of any Contaminant into the Environment that, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect or could result in any violation of any
          Environmental Laws (as defined below) or constitute a health or safety (as such matters relate to Contaminants) or environmental hazard to any person or property except for such violations or hazards that could not reasonably be expected to have
          a Material Adverse Effect&#894; (iii) none of CareTrust, the Operating Partnership or any Subsidiary is aware of any written notice from any governmental body or other person claiming any violation of or liability under any Environmental Laws or
          requiring or calling attention to the need for any work, repairs, construction, alterations, removal or remedial action or installation on or in connection with such real property or improvements relating to the presence of asbestos containing
          materials or other Contaminants on, at, under or migrating to or from such properties, except for such violations, work, repairs, construction, alterations, removal or remedial actions or installations as would not, individually or in the
          aggregate, reasonably be expected to have a Material Adverse Effect&#894; (iv) any such work, repairs, construction, alterations, removal or remedial action or installation, if required, would not result in the incurrence of liabilities, which,
          individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect&#894; (v) none of the Subsidiaries has caused or suffered to exist or occur any condition on any of the properties or improvements of CareTrust, the
          Operating Partnership or any Subsidiary that could give rise to the imposition of any Lien under any Environmental Laws, except such Liens which, individually or in the aggregate, would not reasonably be expected to have a Material Adverse
          Effect&#894; (vi) no real property or improvements owned or leased by any Subsidiary is being used, or to the knowledge of CareTrust, the Operating Partnership or any Subsidiary, has been used, for manufacturing or for any other operations that
          involve or involved the use, handling, transportation, storage, treatment or Release of any Contaminant, where such operations require or required permits or are or were otherwise regulated pursuant to the Environmental Laws and where such
          permits have not been or were not obtained or such regulations or such permits are not being or were not complied with, except in all instances where any failure to obtain a permit or comply with any regulation or permit could not reasonably be
          expected, individually or in the aggregate, to have a Material Adverse Effect&#894; (vii) none of CareTrust, the Operating Partnership or any Subsidiary is aware of any facts or issues relating to compliance with Environmental Law that would
          reasonably be expected to have a Material Adverse Effect on their capital expenditures, earnings or competitive position&#894; and (viii) there are no proceedings that are pending against CareTrust, the Operating Partnership or any Subsidiary to which
          a governmental entity is also a party, other than such proceedings as to which CareTrust reasonably believes that no monetary sanctions of $300,000 (or, if the CareTrust has so elected pursuant to Item 103(c)(3)(iii) of Regulation S-K, the lesser
          of $1,000,000 or one percent of the current assets of CareTrust and its Subsidiaries on a consolidated basis) or more will be imposed.&#160; &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Contaminant</font>&#8221;
          means any pollutant, contaminant, hazardous substance, toxic substance, hazardous waste, special waste, biohazardous waste, petroleum or petroleum derived substance or waste, asbestos or asbestos containing materials, PCBs, lead, pesticides, per-
          or polyfluoroalkyl substances, toxic mold, radon or radioactive materials or any constituent of any such substance or waste, including any substance, material or waste identified or regulated under any Environmental Law.&#160; &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Environmental Laws</font>&#8221; means the Comprehensive Environmental Response, Compensation and Liability Act, 42 U.S.C. &#167; 9601 et seq., the Resource Conservation and
          Recovery Act, 42 U.S.C. &#167; 6901 et seq., the Clean Air Act, 42 U.S.C. &#167; 7401 et seq., the Clean Water Act, 33 U.S.C. &#167; 1251 et seq., the Toxic Substances Control Act, 15 U.S.C. &#167; 2601 et seq., the Occupational Safety and Health Act, 29 U.S.C. &#167;
          651 et seq., and all other federal, state and local laws, common law, ordinances, regulations, rules, orders, decisions, permits, and the like, which are directed at the protection of human health (as it relates to Contaminants) or the
          Environment.&#160; &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Environment</font>&#8221; means any surface water, drinking water, ground water, land surface, subsurface strata, river sediment, buildings, structures,
          and ambient, workplace and indoor air.&#160; &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Release</font>&#8221; means any spilling, leaking, pumping, pouring, emitting, emptying, discharging, injecting, escaping,
          leaching, migrating, dumping, emanating or disposing of any Contaminant into the Environment, including, without limitation, the abandonment or discard of barrels, containers, tanks or other receptacles containing or previously containing any
          Contaminant or any release, emission or discharge as those terms are defined or used in any Environmental Law.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(bb)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">None of CareTrust, the Operating
          Partnership and the Subsidiaries participate in, submit claims to, or receive payment from the Medicare program, the respective Medicaid program in the state or states in which such entity operates, or any other third party payor program.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">11</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(cc)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">CareTrust, the Operating Partnership
          and the Subsidiaries, to the extent applicable in connection with their business, are in compliance with the Health Insurance Portability and Accountability Act of 1996 (as amended, and including 45 C.F.R. Part 160 and Part 164 and any other
          regulations promulgated thereunder) (collectively, &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">HIPAA</font>&#8221;) and with applicable provisions of Federal or state laws governing Medicare or any state
          Medicaid programs and any regulations promulgated pursuant to such laws, including, without limitation, Sections 1320a-7, 1320a-7a, 1320a-7b and 1395nn of Title 42 of the United States Code, the False Claims Act, 31 U.S.C. &#167; 3729 et seq., all
          criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. &#167; 286 and 18 U.S.C. &#167; 287, and the health care fraud criminal provisions under HIPAA (18 U.S.C. &#167; 1347), Medicare (Title XVIII of the Social Security
          Act), Medicaid (Title XIX of the Social Security Act) and related state or local regulations promulgated under such laws (collectively, &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Health Care Laws</font>&#8221;),

          corporate integrity and settlement agreements or any rules of professional conduct, except for such provisions the violation of which would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.&#160;
          CareTrust, the Operating Partnership and the Subsidiaries have not engaged in activities that are, as applicable, cause for false claims liability or civil penalties under the Health Care Laws.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(dd)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">[Reserved]</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(ee)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">[Reserved]</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(ff)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">[Reserved]</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(gg)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">CareTrust, the Operating Partnership
          and the Subsidiaries have filed all foreign, federal, state, local and franchise tax returns that are required to be filed or have obtained extensions thereof, except where the failure so to file would not, individually or in the aggregate,
          reasonably be expected to result in a Material Adverse Effect, and have paid all taxes (including, without limitation, any estimated taxes) required to be paid and any other assessment, fine or penalty, to the extent that any of the foregoing is
          due and payable, except for any such tax, assessment, fine or penalty that is currently being contested in good faith by appropriate actions and except for such taxes, assessments, fines or penalties the nonpayment of which would not,
          individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(hh)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">Commencing with CareTrust&#8217;s taxable
          year ending December 31, 2014, CareTrust has been and is organized and operated in conformity with the requirements for qualification and taxation as a &#8220;real estate investment trust&#8221; (a &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">REIT</font>&#8221;) under Sections 856 through 860 of the Internal Revenue Code of 1986 (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Code</font>&#8221;)&#894; and CareTrust&#8217;s proposed
          method of operation as described in the Disclosure Package and Prospectus will enable CareTrust to meet the requirements for qualification and taxation as a REIT under the Code.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(ii)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-family: 'Times New Roman';">None of CareTrust, the Operating
          Partnership or any Subsidiary is party to any tax sharing or other revenue sharing agreement, other than the Tax Matters Agreement, dated as of May 30, 2014, by and between The Ensign Group, Inc. and CareTrust.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">12</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(jj)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">Except as would not, individually or
          in the aggregate, reasonably be expected to have a Material Adverse Effect, CareTrust, the Operating Partnership and the Subsidiaries have title insurance on all real property and improvements owned by or leased to any of them under a ground
          lease, as the case may be, in each case in an amount at least equal to the original cost of acquisition, and CareTrust, the Operating Partnership or a Subsidiary, as applicable, is entitled to all benefits of the insured thereunder.&#160; Each such
          property is insured by extended coverage hazard and casualty insurance in amounts and on such terms as are customarily carried by owners and, if applicable, lessors and lessees, of similar properties (in the markets in which the properties of
          CareTrust, the Operating Partnership and the Subsidiaries are located).&#160; CareTrust, the Operating Partner and the Subsidiaries carry comprehensive general liability insurance and such other insurance as is customarily carried by owners and, if
          applicable, lessors of properties similar to those leased to or owned by CareTrust, the Operating Partnership and the Subsidiaries, and require the lessee under each lease of any such property to a third party to carry comprehensive general
          liability insurance and such other insurance as is customarily carried by lessees, in each case in amounts and on such terms as are customarily carried by owners, lessors and lessees, as applicable, of similar properties (in the markets in which
          the properties of CareTrust, the Operating Partnership and the Subsidiaries are located).&#160; CareTrust, the Operating Partnership or Subsidiary, as applicable, is named as an additional insured on all policies required to be carried by third-party
          lessees under the leases for such properties.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(kk)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">None of the Operating Partnership or
          any Subsidiary is a party to or otherwise bound by any instrument or agreement that limits or prohibits or could limit or prohibit, directly or indirectly, any Subsidiary from paying any dividends or making any other distributions on its capital
          stock, limited or general partnership interests, limited liability company interests, or other equity interests, as the case may be, or from repaying any loans or advances from, or (except for instruments or agreements that by their express terms
          prohibit the transfer or assignment thereof or of any rights thereunder) transferring any of its properties or assets to, the Operating Partnership or any other Subsidiary, in each case except as described in the Disclosure Package and the
          Prospectus.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(ll)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">The consolidated financial statements
          of CareTrust, together with the related schedule and notes thereto, included or incorporated by reference in the Registration Statement, the Disclosure Package and the Prospectus present fairly in all material respects the financial position of
          CareTrust at the dates indicated and the results of operations, changes in invested equity and cash flows of CareTrust for the periods specified.&#160; Such financial statements have been prepared in conformity with generally accepted accounting
          principles or &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">GAAP</font>&#8221; (as defined in Item 10 of Regulation S-K), applied on a consistent basis throughout the periods involved and comply with all
          applicable accounting requirements under the Securities Act, or the Exchange Act, as applicable, and no other financial statements or supporting schedules are required to be included in the Registration Statement, the Disclosure Package or the
          Prospectus pursuant to Rule 3-14 of Regulation S-X or otherwise.&#160; The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the required information called
          for in all material respects and has been prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">13</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(mm)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Except as otherwise disclosed in the
          Registration Statement, the Disclosure Package and the Prospectus, subsequent to the respective dates as of which information is given in the Prospectus, neither CareTrust, the Operating Partnership nor any of the Subsidiaries has sustained any
          loss or interference with its business material to CareTrust, the Operating Partnership and the Subsidiaries considered as a whole, and there has not been any (i) material change in the capitalization of CareTrust, the Operating Partnership or
          the Subsidiaries, (ii) material increase in the aggregate in the consolidated short-term or long-term debt of CareTrust, (iii) transaction that is material to CareTrust, the Operating Partnership or any of the Subsidiaries contemplated or entered
          into by CareTrust, the Operating Partnership or any of the Subsidiaries, (iv) obligation, contingent or otherwise, directly or indirectly incurred by CareTrust, the Operating Partnership or any Subsidiary that is material to CareTrust, the
          Operating Partnership and the Subsidiaries taken as a whole, (v) dividend or distribution of any kind declared, paid or made by CareTrust on any class of its capital stock (other than regular quarterly cash dividends), or (vi) Material Adverse
          Effect.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(nn)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Deloitte &amp; Touche LLP, who has
          certified the financial statements and supporting schedules of CareTrust incorporated by reference in the Registration Statement, Disclosure Package and the Prospectus and who has delivered the comfort letter referred to in Section 6(g) hereof,
          is an independent public accountant as required by the Exchange Act and is registered with the Public Company Accounting Oversight Board (&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">PCAOB</font>&#8221;).</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(oo)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">[Reserved]</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(pp)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">CareTrust maintains a system of
          internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that complies with the requirements of the Exchange Act and has been designed by CareTrust&#8217;s principal executive officer and principal financial
          officer, or under their supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.&#160;
          As of the date hereof, except as disclosed in the Registration Statement, the Disclosure Package and the Prospectus, neither CareTrust nor the Operating Partnership is aware of (i) any &#8220;significant deficiency&#8221; or &#8220;material weakness&#8221; (in each
          case, as defined in PCAOB No. 5) in CareTrust&#8217;s internal control over reporting, whether or not subsequently remediated, or (ii) any fraud, whether or not material, that involves management or other employees who have a significant role in
          CareTrust&#8217;s internal control over financial reporting.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(qq)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">CareTrust maintains disclosure
          controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) that comply with the requirements of the Exchange Act, which controls and procedures (i) are designed to ensure that material information relating to CareTrust,
          including its consolidated subsidiaries, is made known to CareTrust&#8217;s principal executive officer and its principal financial officer by others within those entities, particularly during the periods in which the periodic reports required under
          the Exchange Act are being prepared and (ii) are effective in all material respects to perform the functions for which they were established, in each case, except as disclosed in the Registration Statement, the Disclosure Package and the
          Prospectus.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(rr)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-family: 'Times New Roman';">There is and has been no failure on
          the part of CareTrust, the Operating Partnership or any Subsidiary, nor, to the knowledge of CareTrust, the Operating Partnership or any of the Subsidiaries, any of their respective directors, members or managers, as applicable, or officers, in
          their capacities as such, to comply in all material respects with any applicable provision of and the rules and regulations under the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in connection therewith, including, without
          limitation, Section 402 related to loans and Sections 302 and 906 related to certifications.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">14</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(ss)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-family: 'Times New Roman';">Nothing has come to the attention of
          CareTrust, the Operating Partnership or any of the Subsidiaries that has caused CareTrust, the Operating Partnership or any Subsidiary to believe any statistical, demographic, market-related and similar data included in the Registration
          Statement, the Disclosure Package or the Prospectus is not based on or derived from sources that CareTrust, the Operating Partnership and the Subsidiaries believe to be reliable and accurate in all material respects.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(tt)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">The Common Stock is registered under
          Section 12(b) of the Exchange Act, and the Shares are listed on the New York Stock Exchange (&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">NYSE</font>&#8221;), and CareTrust has taken no action designed to, or
          likely to have the effect of, terminating the registration of the Shares under the Exchange Act or delisting the Shares from NYSE, nor has CareTrust received any notification that the Commission or NYSE is contemplating terminating such
          registration or listing.&#160; Except as otherwise disclosed in the Prospectus, CareTrust is in material compliance with all applicable listing requirements of NYSE.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(uu)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">CareTrust is not, nor upon the
          issuance and sale of the Shares as herein contemplated and the receipt and application of the net proceeds therefrom as described in the Registration Statement, the Disclosure Package and the Prospectus under the caption &#8220;Use Of Proceeds,&#8221; will
          be, an &#8220;investment company&#8221; or an entity &#8220;controlled&#8221; by an &#8220;investment company&#8221; as such terms are defined in the Investment Company Act of 1940, as amended.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(vv)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-family: 'Times New Roman';">None of CareTrust, the Operating
          Partnership or the Subsidiaries has taken or will take, directly or indirectly, any action designed to or that would constitute or that could reasonably be expected to cause or result in the stabilization or manipulation of the price of any
          security of CareTrust to facilitate the sale or resale of the Shares.&#160; None of CareTrust, the Operating Partnership or the Subsidiaries has taken action that would directly or indirectly violate any provision of Regulation M under the Exchange
          Act (&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Regulation M</font>&#8221;).</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(ww)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">None of CareTrust, the Operating
          Partnership or any Subsidiary or any director, officer, agent, employee, affiliate or other person acting on behalf of CareTrust, the Operating Partnership or any Subsidiary is aware of or has taken any action, directly or indirectly, that has
          resulted or would result in a violation by any such person of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">FCPA</font>&#8221;), or any other applicable anti-bribery or anti-corruption law, including, without limitation, any offer, payment, promise to pay or authorization of the payment of any money or other property, gift, promise to give or
          authorization of the giving of anything of value to any &#8220;foreign official&#8221; (as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention of the FCPA and
          CareTrust, the Operating Partnership and the Subsidiaries, and their respective affiliates have conducted their businesses in compliance with the FCPA and all other applicable anti-bribery and anti-corruption laws and have instituted and maintain
          policies and procedures designed to ensure, and which are reasonably expected to ensure, continued compliance therewith.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">15</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(xx)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">The operations of CareTrust, the
          Operating Partnership and Subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, those of
          the Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), the money laundering statutes of all applicable
          jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Money Laundering Laws</font>&#8221;) and no action, suit or proceeding by or before any court or governmental or regulatory agency, authority or body or any arbitrator involving CareTrust, the Operating Partnership or any
          Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of CareTrust, the Operating Partnership or Subsidiaries, is threatened.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(yy)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">[Reserved]</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(zz)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">None of <a name="z_Hlk198298829"></a><a name="z_Hlk198298509"></a>CareTrust, the Operating Partnership or any Subsidiary or any director, officer, employee, authorized agent or controlled affiliate acting on behalf of CareTrust, the Operating Partnership or any Subsidiary is
          currently (i) the subject or the target of any sanctions administered or enforced by the U.S. government, (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">OFAC</font>&#8221;) or the U.S. Department of State and including, without limitation, the designation as a &#8220;specially designated national&#8221; or &#8220;blocked person&#8221;), the United Nations Security
          Council, the European Union, His Majesty&#8217;s Treasury or other relevant sanctions authority (collectively, &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Sanctions</font>&#8221; and such persons, &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Sanctioned Persons</font>&#8221;), or (ii) located, organized, incorporated or resident in a country or territory that is the subject or the target of country-wide or
          territory-wide Sanctions, including, without limitation, the Crimea, Zaporizhzhia and Kherson Regions of Ukraine, the so-called Donetsk People&#8217;s Republic, the so-called Luhansk People&#8217;s Republic, Cuba,&#8239;Iran and North Korea (each, a &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Sanctioned Country</font>&#8221;). CareTrust and the Operating Partnership will not directly or indirectly use any of the proceeds of the Offering, or lend, contribute or
          otherwise make available such proceeds to any Subsidiary, joint venture partner or other person or entity (A) to fund or facilitate any activities of or business with or for the benefit of any Sanctioned Person, (B) to fund or facilitate any
          activities of or any business in or with any Sanctioned Country, or (C) in any other manner that could result in a violation by any person or entity of any Sanctions.<a name="z_Hlk198300934"></a> Since April 24, 2019, CareTrust, the Operating
          Partnership and Subsidiaries have not engaged in, are not now engaged in and will not engage in any dealings or transactions (A)&#8239;with or for the benefit of any Sanctioned Person or (B)&#8239;in or with any Sanctioned Country or Syria.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(aaa)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">There is not a broker, finder or other
          party that is entitled to receive from CareTrust, the Operating Partnership or any Subsidiary any brokerage or finder&#8217;s fee or other fee or commission as a result of any of the transactions contemplated by this Agreement, except for underwriting
          discounts and commissions payable to the Underwriters in connection with the sale of the Shares pursuant to this Agreement.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(bbb)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">No forward-looking statement (within
          the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act) included or incorporated by reference in the Registration Statement, the Disclosure Package or the Prospectus has been made or reaffirmed without a reasonable
          basis or has been disclosed other than in good faith.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">16</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(ccc)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">The Common Stock is an
          &#8220;actively-traded security&#8221; excepted from the requirements of Rule 101 of Regulation M under the Exchange Act by Rule 101(c)(1) thereunder.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(ddd)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Any certificate signed by any officer
          of CareTrust or the Operating Partnership and delivered to the Representatives or to counsel for the Underwriters shall be deemed a representation and warranty by CareTrust or the Operating Partnership, as the case may be, to each Underwriter as
          to the matters covered thereby.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(eee)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Except as otherwise disclosed in the
          Registration Statement, the Disclosure Package and the Prospectus, to the knowledge of CareTrust, (i)(a) there has been no security breach or other compromise of any of the information technology and computer systems, networks, hardware,
          software, data (including the data of their respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of them), equipment or technology of CareTrust, the Operating Partnership or any Subsidiary
          (collectively, &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">IT Systems and Data</font>&#8221;) and (b) none of CareTrust, the Operating Partnership or any Subsidiary has been notified of, or has any knowledge
          of, any event or condition that would reasonably be expected to result in, any security breach or other compromise to their IT Systems and Data, except as would not, in the case of this clause (i), individually or in the aggregate, have a
          Material Adverse Effect&#894; (ii) each of CareTrust, the Operating Partnership and the Subsidiaries is presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or
          governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or
          modification, except as would not, in the case of this clause (ii), individually or in the aggregate, have a Material Adverse Effect&#894; and (iii) each of CareTrust, Operating Partnership and the Subsidiaries has implemented commercially reasonable
          backup and disaster recovery technology.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;">Sale, Purchase and Delivery of Shares</font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">On the basis of the representations,
          warranties and agreements herein contained, but subject to the terms and conditions herein set forth, CareTrust agrees to issue and sell to the several Underwriters the Firm Shares.&#160; On the basis of the representations, warranties and agreements
          herein contained, but subject to the conditions hereinafter stated, each Underwriter agrees, severally and not jointly, to purchase from CareTrust at a purchase price of $30.72 per share (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Purchase Price</font>&#8221;) the respective number of Firm Shares set forth opposite the name of such Underwriter on <font style="font-family: 'Times New Roman';"><u>Schedule I</u></font> hereto.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">On the basis of the representations,
          warranties and agreements contained in this Agreement, and subject to its terms and conditions, CareTrust hereby grants an option to the several Underwriters to purchase, severally and not jointly, the Optional Shares or any portion thereof from
          CareTrust at the Purchase Price.&#160; The Representatives may exercise this right on behalf of the Underwriters in whole or from time to time in part by giving written notice to CareTrust not later than 30 days after the date of this Agreement.&#160; Any
          exercise notice shall specify the number of Optional Shares to be purchased by the Underwriters and the date on which such shares are to be purchased.&#160; Unless otherwise agreed by CareTrust, each purchase date of the Optional Shares must be at
          least three business days after the written notice is given and may not be earlier than the First Delivery Date (as defined below) nor later than ten business days after the date of such notice&#894; provided, however, that if notice is received at
          least one business day prior to the First Delivery Date, the purchase date will be the First Delivery Date.&#160; On each Optional Delivery Date, each Underwriter agrees, severally and not jointly, to purchase the number of Optional Shares (subject to
          such adjustments to eliminate fractional shares as the Representatives may determine) that bears the same proportion to the total number of Optional Shares to be purchased on such Optional Delivery Date as the number of Firm Shares set forth in <font style="font-family: 'Times New Roman';"><u>Schedule I</u></font> hereto opposite the name of such Underwriter bears to the total number of Firm Shares to be purchased on the First Delivery Date.&#160; No Optional Shares shall be sold or delivered
          unless the Firm Shares previously have been, or simultaneously are, sold and delivered.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">17</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">The several Underwriters propose to
          offer the Shares for sale to the public upon the terms and conditions and in the manner set forth in the Prospectus.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">The Shares to be purchased by each
          Underwriter hereunder, in book-entry form and in such authorized denominations and registered in such names as the Representatives may request, shall be delivered by or on behalf of CareTrust to the Underwriters, through the facilities of The
          Depository Trust Company, for the accounts of such Underwriters, against payment by or on behalf of the Underwriter of the purchase price therefor by wire transfer of federal (same-day) funds to the account specified by CareTrust to the
          Representatives at least twenty-four hours in advance.&#160; The date of such delivery and payment shall be, with respect to the Firm Shares, August 14, 2025 or such other time and date as the Representatives and CareTrust may agree upon in writing,
          and, with respect to the Optional Shares, on the date specified by the Representatives in the written notice given by the Representatives of their election to purchase such Optional Shares, or such date as the Representatives and CareTrust may
          agree upon in writing.&#160; Such date for delivery of the Firm Shares is herein called the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">First Delivery Date</font>,&#8221; such date for delivery of the Optional
          Shares, if not the First Delivery Date, is herein called an &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Optional Delivery Date</font>,&#8221; and each such time and date for delivery is herein called a &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Delivery Date</font>.&#8221;</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-family: 'Times New Roman';">Time shall be of the essence, and
          delivery at the time and place specified pursuant to this Agreement is a further condition of the obligations of the Underwriters hereunder.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">3.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;">Certain Agreements of CareTrust</font>.&#160; CareTrust covenants and agrees with each of the Underwriters:</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-family: 'Times New Roman';">To furnish such information as may be
          required and otherwise to cooperate in qualifying the Shares for offering and sale under (or obtain exemptions from the application of) the securities or &#8220;Blue Sky&#8221; laws of such jurisdictions (both domestic and foreign) as the Representatives may
          designate and to maintain such qualifications (or exemptions) in effect as long as requested by the Representatives for the distribution of the Shares, provided that CareTrust shall not be required to qualify as a foreign corporation or to
          consent to the service of process under the laws of any such state (except service of process with respect to the offering and sale of the Shares).</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman';">If, after the time this Agreement is
          executed and delivered, it is necessary for a post-effective amendment to the Registration Statement to become effective before the offering of the Shares may commence, CareTrust will endeavor to cause such post-effective amendment to become
          effective as soon as possible and will advise the Representatives promptly and, if requested by the Representatives, will confirm such advice in writing, when such post-effective amendment has become effective.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">18</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">To prepare the Prospectus in a form
          approved by the Representatives, which approval shall not be unreasonably withheld, delayed or conditioned, and to file such Prospectus pursuant to Rule 424(b) under the Securities Act not later than the Commission&#8217;s close of business on the
          second business day following the execution and delivery of this Agreement&#894; during the period beginning on the date hereof and ending on the date, which in the opinion of counsel for the Underwriters, a prospectus is no longer required by law to
          be delivered in connection with the offering and sales of the Shares, to make no further amendment or any supplement to the Registration Statement, the Disclosure Package or Prospectus (including any amendment or supplement through incorporation
          of any report filed under the Exchange Act) which shall be disapproved by the Representatives promptly after reasonable notice thereof, provided that CareTrust may file any information required to be filed by Sections 13(a), 13(c) or 15(d) of the
          Exchange Act upon reasonable notice to the Representatives irrespective of disapproval by the Representatives&#894; to advise the Representatives, promptly after it receives notice thereof, of the time when any amendment to the Registration Statement
          has been filed or becomes effective or any supplement to the Prospectus or any amended Prospectus has been filed and to furnish the Representatives with copies thereof&#894; to file promptly, and in any event within the time periods specified, all
          reports and any definitive proxy or information statements required to be filed by CareTrust pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus for so long as the delivery of a prospectus
          (or in lieu thereof, the notice referred to in Rule 173(a) under the Securities Act) is required in connection with the offering or sale of the Shares&#894; to advise the Representatives, promptly after it receives notice thereof, of the issuance by
          the Commission of any stop order or of any order preventing or suspending the use of the Time of Sale Prospectus or the Prospectus or any other prospectus in respect of the Shares, of the suspension of the qualification of the Shares for offering
          or sale in any jurisdiction, of the initiation or threatening of any proceeding for any such purpose or pursuant to Section 8A of the Securities Act, or of any request by the Commission for the amending or supplementing of the Registration
          Statement or Prospectus or for additional information&#894; and, in the event of the issuance of any stop order or of any order preventing or suspending the use of the Time of Sale Prospectus or the Prospectus or other prospectus or suspending any
          such qualification, promptly to use its reasonable best efforts to obtain the withdrawal of such order.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">19</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-family: 'Times New Roman';">No later than 5:30 p.m., Eastern
          time, on the second business day succeeding the date of this Agreement, and from time to time, to furnish the Underwriters with electronic copies of the Disclosure Package and the Prospectus in such quantities as the Representatives may
          reasonably request, and, (i) if at any time prior to the First Delivery Date,&#8239;any events shall have occurred as a result of which the Disclosure Package as then amended or supplemented would include an untrue statement of a material fact or omit
          to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made when the Disclosure Package is delivered, not misleading or, if for any other reason it shall be
          necessary&#8239;during such period to amend or supplement the Disclosure Package to comply with the Securities Act, to notify the Representatives and upon their request to prepare and furnish without charge to each Underwriter and to any dealer in
          securities as many written and electronic copies as the Representatives may from time to time reasonably request of such amendments or supplements to the Disclosure Package (or any document to be filed with the Commission and incorporated by
          reference therein) which will correct such statement or omission or effect such compliance, or (ii) if the delivery of a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Securities Act) is required at any time prior
          to the expiration of nine months after the time of issue of the Prospectus in connection with the offering or sale of the Shares and if at such time any events shall have occurred as a result of which the Prospectus as then amended or
          supplemented would include an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made when such Prospectus (or in lieu
          thereof, the notice referred to in Rule 173(a) under the Securities Act) is delivered, not misleading, or, if for any other reason it shall be necessary during such period to amend or supplement the Prospectus in order to comply with the
          Securities Act, to notify the Representatives and upon their request to prepare and furnish without charge to each Underwriter and to any dealer in securities as many written and electronic copies as the Representatives may from time to time
          reasonably request of an amended Prospectus or a supplement to the Prospectus which will correct such statement or omission or effect such compliance, and in case any Underwriter is required by law, rule or regulation to deliver a prospectus (or
          in lieu thereof, the notice referred to in Rule 173(a) under the Securities Act) in connection with sales of any of the Shares at any time nine months or more after the time of issue of the Prospectus, upon the request of the Representatives but
          at the expense of such Underwriter, to prepare and deliver to such Underwriter as many written and electronic copies as the Representatives may reasonably request of an amended or supplemented Prospectus complying with Section 10(a)(3) of the
          Securities Act.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">To make generally available to its
          security holders via EDGAR within the required time periods after the effective date of the Registration Statement (as the term &#8220;effective date&#8221; is defined in Rule 158(c) under the Securities Act), an earnings statement of CareTrust and its
          consolidated subsidiaries (which need not be audited) complying with the provisions of Section 11(a) of the Securities Act (including, at the option of CareTrust, Rule 158 under the Securities Act).</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(f)</font><font style="font-size: 10pt;">&#160;&#160;&#160; &#160; &#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">During the period beginning from the
          date hereof and continuing to and including the date 45 days after the date of the Prospectus, except as provided hereunder, not to, directly or indirectly, offer, sell, contract to sell, pledge or otherwise dispose of (or enter into any
          transaction or device which is designed to, or could be expected to, result in the disposition of) any shares of Common Stock or any securities that are substantially similar to the Common Stock or securities convertible into or exchangeable for
          Common Stock or any securities that are substantially similar to the Common Stock, or sell or grant options, rights or warrants with respect to any shares of Common Stock or any securities that are substantially similar to Common Stock or
          securities convertible into or exchangeable for Common Stock or any securities that are substantially similar to Common Stock, or publicly announce the intention to do any of the foregoing, without the prior written consent of the
          Representatives, except, in each case (A) the sale of the Shares and (B) the issuance, grant or sale of shares of Common Stock, options to purchase Common Stock, stock units to purchase Common Stock or Common Stock issuable upon the exercise of
          options, stock units or other equity awards granted pursuant to employee benefit or stock incentive plans of CareTrust existing on the date of this Agreement and referred to in the Registration Statement.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">20</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(g)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">During a period of two years from the
          effective date of the Registration Statement, to deliver or to make available via EDGAR to the Representatives promptly after they become available, copies of any reports and financial statements of CareTrust filed with the Commission under the
          Exchange Act or mailed to its stockholders.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(h)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">To engage and maintain, at its
          expense, a registrar and transfer agent for the Shares.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(i)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-family: 'Times New Roman';">Prior to termination of the
          underwriting syndicate contemplated by this Agreement and during the offering of the Shares by the Underwriters for sale to the public in the manner set forth in the Prospectus, not to, and to use its best efforts to cause its officers, directors
          and affiliates not to, (i) take, directly or indirectly, any action designed to stabilize or manipulate the price of any security of CareTrust, or which may cause or result in, or which might in the future reasonably be expected to cause or
          result in, the stabilization or manipulation of the price of any security of CareTrust, to facilitate the sale or resale of any of the Shares, (ii) sell, bid for, purchase or pay anyone any compensation for soliciting purchases of the Shares or
          (iii) pay or agree to pay any person any compensation for soliciting any order to purchase any other securities of CareTrust.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(j)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-family: 'Times New Roman';">To comply with all of the
          provisions of any undertakings in the Registration Statement.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">4.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;">Additional Agreements</font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-family: 'Times New Roman';">CareTrust represents and agrees that,
          without the prior consent of the Representatives, it has not made and will not make any offer relating to the Shares that would constitute a &#8220;free writing prospectus&#8221; (as defined in Rule 405).&#160; Each Underwriter represents and agrees that, without
          the prior consent of CareTrust and the Representatives, it has not made and will not make any offer relating to the Shares that would be required to be filed by CareTrust as a free writing prospectus.&#160; Any such free writing prospectus the use of
          which has been consented to by CareTrust and the Representatives is listed on <font style="font-family: 'Times New Roman';"><u>Schedule II</u></font> or <font style="font-family: 'Times New Roman';"><u>Schedule III</u></font> hereto.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">CareTrust has complied and will comply
          with the requirements of Rule 433 under the Securities Act applicable to any Issuer Free Writing Prospectus, including timely filing with the Commission or retention where required and legending.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-family: 'Times New Roman';">CareTrust agrees that if at any time
          following issuance of an Issuer Free Writing Prospectus any event occurred or occurs as a result of which such Issuer Free Writing Prospectus would conflict with the information in the Registration Statement, the Time of Sale Prospectus or the
          Prospectus or would include an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances then prevailing, not misleading, CareTrust will give prompt
          notice thereof to the Representatives and, if requested by the Representatives, will prepare and furnish without charge to each Underwriter an Issuer Free Writing Prospectus or other document which will correct such conflict, statement or
          omission.&#160; The agreement set forth in the immediately preceding sentence does not apply to statements or omissions made in reliance upon and in conformity with written information furnished to CareTrust by an Underwriter expressly for inclusion
          therein, which information consists solely of the information set forth in <font style="font-family: 'Times New Roman';"><u>Section 7(b)</u></font> hereof.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">21</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">Each of CareTrust and the Operating
          Partnership acknowledge and agree that (i) the Underwriters&#8217; research analysts and research departments are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies
          and (ii) the Underwriters&#8217; research analysts may hold views and make statements or investment recommendations and/or publish research reports with respect to CareTrust, the value of the Common Stock and/or the offering that differ from the views
          of their respective investment banking divisions.&#160; Each of CareTrust and the Operating Partnership hereby waives and releases, to the fullest extent permitted by law, any claims that it may have against the Underwriters with respect to any
          conflict of interest that may arise from the fact that the views expressed by the Underwriters&#8217; independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to CareTrust and/or
          the Operating Partnership by any Underwriter&#8217;s investment banking division.&#160; Each of CareTrust and the Operating Partnership acknowledges that each of the Underwriters is a full service securities firm and as such, from time to time, subject to
          applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of CareTrust.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">5.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;">Expenses</font>.&#160; CareTrust will pay or cause to be paid: (a) the fees, disbursements and expenses of CareTrust&#8217;s counsel and accountants in connection with the registration of the Shares under the Securities Act
          and all other expenses in connection with the preparation, printing and filing of the Registration Statement, any preliminary prospectus, any Issuer Free Writing Prospectus and the Prospectus and amendments and supplements thereto and the mailing
          and delivering of copies thereof to the Underwriters and dealers&#894; (b) the cost of printing or producing of a reasonable number of each of any preliminary prospectuses, the Prospectus (including any amendments and supplements thereto), any Issuer
          Free Writing Prospectus and a &#8220;Blue Sky&#8221; Memorandum&#894; (c) all expenses relating to investor presentations or any &#8220;roadshow&#8221; undertaken in connection with marketing of the Shares (including electronic roadshows)&#894; (d) all expenses in connection with
          the qualification of the Shares for offering and sale under state securities laws as provided in <font style="font-family: 'Times New Roman';"><u>Section 3(a)</u></font> hereof, including the reasonable and documented fees and disbursements of
          counsel for the Underwriters in connection with such qualification and in connection with the &#8220;Blue Sky&#8221; Memorandum&#894; (e) if applicable, all fees and expenses in connection with listing the Shares on NYSE&#894; (f) the filing fees incident to, and the
          reasonable and documented fees and disbursements of counsel for the Underwriters in connection with, any required review by FINRA of the terms of the sale of the Shares&#894; (g) the cost of preparing share certificates&#894; (h) the cost and charges of
          any transfer agent or registrar&#894; and (i) all other costs and expenses incident to the performance of its obligations hereunder which are not otherwise specifically provided for in this Section.&#160; Except as specifically provided in clauses (c) and
          (e) above, CareTrust shall have no liability for fees or disbursements of counsel for the Underwriters in connection with the transactions contemplated by this Agreement.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;">Conditions of the Obligation of the Underwriters</font>.&#160; The obligations of the several Underwriters hereunder shall be subject to the accuracy, when made and on each Delivery Date, of the representations and
          warranties of CareTrust contained herein, to the performance by CareTrust of its obligations hereunder, and to each of the following additional conditions:</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">22</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">The Prospectus shall have been filed
          with the Commission pursuant to Rule 424(b) within the applicable time period prescribed for such filing by the Securities Act and in accordance with <font style="font-family: 'Times New Roman';"><u>Section 3(c)</u></font> hereof&#894; all material
          required to be filed by CareTrust pursuant to Rule 433(d) under the Securities Act shall have been filed with the Commission within the applicable time period prescribed for such filing by Rule 433.&#160; No stop order suspending the effectiveness of
          the Registration Statement or any part thereof shall have been issued and no proceedings for that purpose or pursuant to Section 8A of the Securities Act shall be pending or are, to the best knowledge of CareTrust, threatened by the Commission&#894;
          no stop order suspending or preventing the use of the Prospectus or any Issuer Free Writing Prospectus or any part thereof shall have been issued and no proceedings for that purpose shall be pending or are, to the best knowledge of CareTrust,
          threatened by the Commission&#894; no order suspending the qualification or registration of the Shares under the securities or Blue Sky laws of any jurisdiction shall be in effect and no proceeding for such purpose shall be pending before or are, to
          the best knowledge of CareTrust, threatened by the authorities of any such jurisdiction&#894; all requests for additional information on the part of the Commission shall have been complied with to the reasonable satisfaction of the Representatives&#894;
          and after the date hereof no amendment or supplement to the Registration Statement or the Prospectus relating to the Shares shall have been filed unless a copy thereof was first submitted to the Representatives and the Representatives did not
          object thereto.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">The Underwriters shall not have
          discovered and disclosed to CareTrust prior to or on such Delivery Date that (i) the Registration Statement, or any amendment or supplement thereto, contains an untrue statement of a fact which, in the opinion of counsel for the Underwriters, is
          material or omits to state a fact which, in the opinion of counsel for the Underwriters, is material and is required to be stated therein or is necessary to make the statements therein not misleading, and (ii) any preliminary prospectus, any
          Issuer Free Writing Prospectus or the Prospectus, or any amendment or supplement thereto, contains any untrue statement of a fact which, in the opinion of counsel for the Underwriters, is material or omits to state a fact which, in the opinion of
          counsel for the Underwriters, is material and is required to be stated therein or is necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-family: 'Times New Roman';">O&#8217;Melveny &amp; Myers LLP, counsel
          for CareTrust and the Operating Partnership, shall have furnished to the Representatives their written opinion and negative assurance letter, dated such Delivery Date, in form and substance satisfactory to the Representatives.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">Kirkland &amp; Ellis LLP, counsel for
          CareTrust and the Operating Partnership, shall have furnished to the Representatives their written opinion regarding certain tax matters, dated such Delivery Date, in form and substance satisfactory to the Representatives.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">DLA Piper LLP (US), special Maryland
          counsel for CareTrust, shall have furnished to the Representatives their written opinion, dated such Delivery Date, in form and substance satisfactory to the Representatives.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(f)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">Jones Day, counsel for the
          Underwriters, shall have furnished to the Representatives their written opinion, dated such Delivery Date, in form and substance satisfactory to the Representatives.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">23</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(g)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">The Underwriters shall have
          received, on each of the date hereof and each Delivery Date, a letter dated the date hereof or such Delivery Date, as the case may be, in form and substance satisfactory to the Representatives, from Deloitte &amp; Touche LLP containing statements
          and information of the type ordinarily included in accountants&#8217; &#8220;comfort letters&#8221; to underwriters with respect to the financial statements and certain financial information of CareTrust, as applicable, contained in the Registration Statement, the
          Disclosure Package and the Prospectus, provided that the letter delivered on each Delivery Date shall use a &#8220;cut-off date&#8221; not earlier than the third business day prior to such Delivery Date.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(h)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">CareTrust and the Operating
          Partnership will, on each Delivery Date, deliver to the Underwriters a certificate of an executive officer of CareTrust and an executive officer of the Operating Partnership, dated such Delivery Date, to the effect that:</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160; (i)</font><font style="font-size: 10pt;"> &#160; &#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman';">The representations and warranties
          of each of CareTrust and the Operating Partnership, as applicable, in this Agreement are true and correct, as if made on and as of the date thereof and provided that any reference therein to the First Delivery Date shall be deemed to refer to the
          applicable Delivery Date on which such certificate is delivered&#894; and each of CareTrust and the Operating Partnership has complied with all the agreements and satisfied all the conditions on its part to be performed or satisfied at or prior to
          such Delivery Date&#894;</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(ii)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-family: 'Times New Roman';">No stop order suspending the
          effectiveness of the Registration Statement or any post-effective amendment thereto has been issued and no proceedings for that purpose or pursuant to Section 8A of the Securities Act have been instituted or are pending or are, to the best
          knowledge of CareTrust, threatened under the Securities Act&#894;</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(iii)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">No stop order suspending or
          preventing the use of the Prospectus or any Issuer Free Writing Prospectus or any part thereof has been issued and no proceedings for that purpose have been instituted or are pending or are, to the best knowledge of CareTrust, threatened under
          the Securities Act&#894;</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(iv)</font><font style="font-size: 10pt;">&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-family: 'Times New Roman';">When the Registration Statement
          became effective and at all times subsequent thereto up to the date hereof, the Registration Statement and the Prospectus, and any amendments or supplements thereto, contained all material information required to be included therein by the
          Securities Act or the Exchange Act and the applicable rules and regulations of the Commission thereunder, as the case may be, and in all material respects conformed to the requirements of the Securities Act or the Exchange Act and the applicable
          rules and regulations of the Commission thereunder, as the case may be&#894; the Registration Statement, the Disclosure Package and the Prospectus, and any amendments or supplements thereto, did not and do not include any untrue statement of a
          material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading&#894; and, since the effective date of the
          Registration Statement, there has occurred no event required to be set forth in an amendment or supplemented Prospectus which has not been so set forth&#894; and</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">24</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(v)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Subsequent to the respective dates as
          of which information is given in the Registration Statement, the Disclosure Package and Prospectus, except as set forth in the Disclosure Package and the Prospectus, there has not been any (a) transaction or event which has a Material Adverse
          Effect, (b) change in the capitalization of CareTrust, the Operating Partnership or any Subsidiary that is material to CareTrust, the Operating Partnership and the Subsidiaries taken as a whole, (c) obligation, contingent or otherwise, directly
          or indirectly incurred by CareTrust, the Operating Partnership or any Subsidiary that is material to CareTrust, the Operating Partnership and the Subsidiaries taken as a whole or (d) dividend or distribution of any kind declared, paid or made by
          CareTrust on any class of its capital stock.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(i)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">CareTrust will, on each of the date
          hereof and each Delivery Date, deliver to the Underwriters a certificate of the Chief Financial Officer of CareTrust, dated the date hereof or such Delivery Date, in form and substance satisfactory to the Representatives.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(j)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">(i) Neither CareTrust nor the
          Operating Partnership nor any of the Subsidiaries shall have sustained since the date of the latest audited financial statements included in the Disclosure Package and the Prospectus any loss or interference with its business, otherwise than as
          set forth in the Disclosure Package and the Prospectus and (ii) since the respective dates as of which information is given in the Prospectus, there shall not have been any change in the capitalization of CareTrust or change, or any development
          or event involving a prospective change, on the condition (financial or otherwise), business, properties, business prospects or results of operations of CareTrust, the Operating Partnership and the Subsidiaries, taken as a whole, otherwise than
          as set forth or contemplated in the Disclosure Package and the Prospectus, the effect of which, in any such case described in clause (i) or (ii), is in the judgment of the Representatives so material and adverse as to make it impracticable or
          inadvisable to proceed with the public offering or the delivery of the Shares being delivered on such Delivery Date on the terms and in the manner contemplated in the Disclosure Package and the Prospectus.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(k)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">On or after the date hereof, there
          shall not have occurred any of the following: (i) a suspension or material limitation in trading in securities generally on the NYSE or the Nasdaq Global Select Market, (ii) a suspension or material limitation in trading in CareTrust&#8217;s securities
          on the NYSE, (iii) a general moratorium on commercial banking activities declared by United States federal or New York state authorities or a material disruption in commercial banking or securities settlement or clearance services in the United
          States, (iv) the outbreak or escalation of hostilities involving the United States or the declaration by the United States of a national emergency or war or (v) the occurrence of any other calamity or crisis or any change in financial, political
          or economic conditions in the United States or elsewhere, if the effect of any such event specified in clause (iv) or (v) in the judgment of the Representatives makes it impracticable or inadvisable to proceed with the public offering or the
          delivery of the Shares being delivered on such Delivery Date on the terms and in the manner contemplated in the Disclosure Package and the Prospectus.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(l)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">The Representatives shall have
          received from each person listed on <font style="font-family: 'Times New Roman';"><u>Exhibit B</u></font> hereto an executed lock-up letter agreement substantially to the effect set forth in the form attached hereto as <font style="font-family: 'Times New Roman';"><u>Exhibit A</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(m)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Each of CareTrust and the Operating
          Partnership shall have furnished to the Representatives such further information, certificates and documents as the Representatives may reasonably request.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">25</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">All opinions, certificates, letters and documents mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the
      provisions hereof only if they are in form and substance satisfactory to counsel for the Underwriters.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;">Indemnification and Contribution</font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">CareTrust and the Operating Partnership
          shall, jointly and severally, indemnify and hold harmless each Underwriter, its affiliates, their respective officers, directors, employees and agents, and each person, if any, who controls such indemnified party within the meaning of Section 15
          of the Securities Act or Section 20 of the Exchange Act, against any losses, claims, damages or liabilities, joint or several, to which such Underwriter may become subject, under the Securities Act or otherwise, insofar as such losses, claims,
          damages or liabilities (or actions in respect thereof) arise out of or are based upon (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment or supplement thereto or the
          omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein not misleading, or (ii) any untrue statement or alleged untrue statement of a material fact contained in any preliminary
          prospectus, the Time of Sale Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus or any &#8220;issuer information&#8221; filed or required to be filed pursuant to Rule 433(d) under the Securities Act
          Regulations, or the omission or alleged omission to state therein a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, and will reimburse each indemnified party
          for any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending against any such loss, claim, damage, liability or action as such expenses are incurred&#894; provided, however, that CareTrust
          shall not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in the Registration Statement,
          any preliminary prospectus, the Time of Sale Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus, in reliance upon and in conformity with written information furnished to CareTrust by an
          Underwriter expressly for inclusion therein, which information consists solely of the information described in <font style="font-family: 'Times New Roman';"><u>Section 7(b)</u></font> hereof.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">Each Underwriter, severally and not
          jointly, shall indemnify and hold harmless CareTrust, the Operating Partnership, their affiliates, their respective officers, directors, employees and agents, and each person, if any, who controls CareTrust within the meaning of Section 15 of the
          Securities Act or Section 20 of the Exchange Act against any losses, claims, damages or liabilities to which such indemnified party may become subject, under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities
          (or actions in respect thereof) arise out of or are based upon (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment or supplement thereto or the omission or alleged
          omission of a material fact required to be stated therein or necessary to make the statements therein not misleading&#894; or (ii) any untrue statement or alleged untrue statement of a material fact contained in any preliminary prospectus, the Time of
          Sale Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus or any &#8220;issuer information&#8221; filed or required to be filed pursuant to Rule 433(d) under the Securities Act Regulations, or the
          omission or alleged omission to state therein a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, in each case to the extent, but only to the extent, that such
          untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer
          Free Writing Prospectus, in reliance upon and in conformity with written information furnished to CareTrust by such Underwriter expressly for inclusion therein, and will reimburse each indemnified party for any legal or other expenses reasonably
          incurred by such indemnified party in connection with investigating or defending against any such loss, claim, damage, liability or action as such expenses are incurred.&#160; Each of CareTrust and the Operating Partnership hereby acknowledges that
          the only written information that the Underwriters have furnished to CareTrust and the Operating Partnership expressly for use in the Time of Sale Prospectus and the Prospectus consists solely of the statements set forth in the Time of Sale
          Prospectus and the Prospectus in the table in the first paragraph and as set forth in the fifth paragraph, the twelfth paragraph, the thirteenth paragraph and the fifteenth paragraph under the caption, &#8220;Underwriting.&#8221;</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">26</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">Promptly after receipt by an
          indemnified party under this <font style="font-family: 'Times New Roman';"><u>Section 7</u></font> of notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying
          party under <font style="font-family: 'Times New Roman';"><u>Sections 7(a)</u></font> or 7<font style="font-family: 'Times New Roman';"><u>(b)</u></font> hereof, notify the indemnifying party in writing of the commencement thereof&#894; but the
          omission so to notify the indemnifying party will not relieve it from any liability which it may have to any indemnified party otherwise than under <font style="font-family: 'Times New Roman';"><u>Sections 7(a)</u></font> or 7<font style="font-family: 'Times New Roman';"><u>(b)</u></font> hereof.&#160; In case any such action is brought against any indemnified party and it notifies the indemnifying party of the commencement thereof, the indemnifying party shall be entitled to
          participate therein and, to the extent that it may wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel reasonably satisfactory to such indemnified party (who shall not, except with the
          consent of the indemnified party, be counsel to the indemnifying party), and, except as provided in the following sentence, after notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof, the
          indemnifying party will not be liable to such indemnified party under this Section for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof other than reasonable costs of
          investigation.&#160; After notice from the indemnifying party to the indemnified party of the indemnifying party&#8217;s election to assume the defense of such action, the indemnified party shall have the right to employ its own counsel in any such action,
          but the fees and expenses of such counsel shall be at the expense of such indemnified party unless (i) the indemnifying party and the indemnified party shall have mutually agreed to the retention of such counsel, (ii) if the named parties in any
          such action include both the indemnifying party and the indemnified party and the indemnified party shall have reasonably concluded that there is an actual or potential conflict between the positions of the indemnifying party and the indemnified
          party in conducting the defense of any such action or that there may be legal defenses available to it or other indemnified parties that are different from or additional to those available to the indemnifying party or (iii) the indemnifying party
          shall not have employed counsel to assume the defense of such action within a reasonable time after notice of commencement thereof, in each of which cases the fees and expenses of such counsel shall be at the expense of the indemnifying party (it
          being understood, however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate counsel in addition to any local counsel).&#160; No indemnifying party shall, without the prior written consent of the
          indemnified party, effect any settlement or compromise of, or consent to the entry of any judgment with respect to, any pending or threatened action or claim in respect of which indemnification or contribution may be sought hereunder (whether or
          not the indemnified party is an actual or potential party to such action or claim) unless such settlement, compromise or judgment (i) includes an unconditional release of the indemnified party from all liability arising out of such action or
          claim and (ii) does not include a statement as to or an admission of fault, culpability or failure to act by or on behalf of any indemnified party.&#160; The indemnifying party shall not be liable for any settlement of any proceeding effected without
          its written consent but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of such settlement or
          judgment.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">27</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-family: 'Times New Roman';">If the indemnification provided for
          in this Section is unavailable to or insufficient to hold harmless an indemnified party under <font style="font-family: 'Times New Roman';"><u>Sections 7(a)</u></font> or 7<font style="font-family: 'Times New Roman';"><u>(b)</u></font> hereof in
          respect of any losses, claims, damages or liabilities (or actions in respect thereof) referred to therein, then each indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims,
          damages or liabilities (or actions in respect thereof) in such proportion as is appropriate to reflect the relative benefits received by CareTrust and the Operating Partnership and the Underwriters, respectively, from the offering of the Shares.&#160;
          If, however, the allocation provided by the immediately preceding sentence is not permitted by applicable law, then each indemnifying party shall contribute to such amount paid or payable by such indemnified party in such proportion as is
          appropriate to reflect not only the relative benefits but also the relative fault of CareTrust and the Operating Partnership and the Underwriters, respectively, in connection with the statements or omissions which resulted in such losses, claims,
          damages or liabilities (or actions in respect thereof), as well as any other relevant equitable considerations.&#160; The relative benefits received by CareTrust and the Operating Partnership and the Underwriters, respectively, shall be deemed to be
          in the same proportion as the total net proceeds from the offering (net of underwriting discounts and commissions but before deducting expenses) received by CareTrust bear to the total underwriting discounts and commissions received by the
          Underwriters, in each case as set forth in the table on the cover page of the Prospectus.&#160; The relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the
          omission or alleged omission to state a material fact relates to information supplied by CareTrust or the Operating Partnership or the Underwriters and the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or
          prevent such untrue statement or omission.&#160; CareTrust and the Operating Partnership and the Underwriters agree that it would not be just and equitable if contributions pursuant to this <font style="font-family: 'Times New Roman';"><u>Section
              7(d)</u></font> were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to above in this <font style="font-family: 'Times New Roman';"><u>Section 7(d)</u></font>.&#160;

          The amount paid or payable by an indemnified party as a result of the losses, claims, damages or liabilities (or actions in respect thereof) referred to above in this <font style="font-family: 'Times New Roman';"><u>Section 7(d)</u></font> shall
          be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim based upon any such untrue or alleged untrue statement or omission or alleged
          omission.&#160; Notwithstanding the provisions of this <font style="font-family: 'Times New Roman';"><u>Section 7(d)</u></font>, no Underwriter shall be required to contribute any amount in excess of the amount by which the underwriting discounts and
          commissions applicable to the Shares purchased by such Underwriter exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of any such untrue or alleged untrue statement or omission or alleged
          omission.&#160; No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">28</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;">Default of the Several Underwriters</font>.&#160; If, on any Delivery Date, any one or more of the several Underwriters shall fail or refuse to purchase Shares that it or they have agreed to purchase hereunder on such
          date, and the aggregate number of Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase does not exceed 10% of the aggregate number of the Shares to be purchased on such date, the other Underwriters
          shall be obligated, severally, in the proportions that the number of shares of Common Stock set forth opposite their respective names on <font style="font-family: 'Times New Roman';"><u>Schedule I</u></font> hereto bears to the aggregate number
          of shares of Common Stock set forth opposite the names of all such non-defaulting Underwriters, or in such other proportions as may be specified by the Representatives with the consent of the non-defaulting Underwriters, to purchase the Shares
          which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase on such date.&#160; If, on any Delivery Date, any one or more of the Underwriters shall fail or refuse to purchase Shares and the aggregate number of Shares
          with respect to which such default occurs exceeds 10% of the aggregate number of Shares to be purchased on such date, and arrangements satisfactory to the Representatives and CareTrust and the Operating Partnership for the purchase of such Shares
          are not made within forty-eight hours after such default, this Agreement shall terminate without liability of any non-defaulting party to any other party except that the provisions of <font style="font-family: 'Times New Roman';"><u>Sections 5</u></font>
          and <font style="font-family: 'Times New Roman';"><u>7</u></font> hereof shall at all times be effective and shall survive such termination.&#160; In any such case, either the Representatives or CareTrust and the Operating Partnership shall have the
          right to postpone the Delivery Date but in no event for longer than seven days in order that the required changes, if any, to the Registration Statement and the Prospectus or any other documents or arrangements may be effected.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">9.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;">Termination</font>.&#160; The obligations of the Underwriters hereunder may be terminated by the Underwriters by notice given to and received by CareTrust and the Operating Partnership prior to delivery of and payment
          for the Firm Shares or the Optional Shares, respectively, if, prior to that time, any of the events described in <font style="font-family: 'Times New Roman';"><u>Sections 6(j)</u></font> or <font style="font-family: 'Times New Roman';"><u>6(k)</u></font>
          hereof shall have occurred or if the Underwriters shall decline to purchase such Shares for any reason permitted under this Agreement other than pursuant to <font style="font-family: 'Times New Roman';"><u>Section 8</u></font>.&#160; In such case,
          CareTrust shall have no liability hereunder except as provided by <font style="font-family: 'Times New Roman';"><u>Sections 5</u></font>, <font style="font-family: 'Times New Roman';"><u>7</u></font> and <font style="font-family: 'Times New Roman';"><u>10</u></font> hereof.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">10.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;">Reimbursement of Underwriters&#8217; Expenses</font>.&#160; If (a) CareTrust shall fail to tender the Shares for delivery to the Underwriters for any reason under this Agreement other than a breach by the Underwriters of their
          representations herein or obligations hereunder or (b) the Underwriters shall decline to purchase the Shares for any reason permitted under this Agreement other than pursuant to <font style="font-family: 'Times New Roman';"><u>Section 8</u></font>
          (including the termination of this Agreement pursuant to <font style="font-family: 'Times New Roman';"><u>Section 9</u></font> hereof, other than by reason of the occurrence of any event specified in <font style="font-family: 'Times New Roman';"><u>Sections 6(k)(i)</u></font>, <font style="font-family: 'Times New Roman';"><u>(iii)</u></font>, <font style="font-family: 'Times New Roman';"><u>(iv)</u></font> or <font style="font-family: 'Times New Roman';"><u>(v)</u></font>
          hereof, but excluding the failure of any of the conditions herein to be satisfied as a result of a breach by the Underwriters of their representations herein), CareTrust and the Operating Partnership shall reimburse the Underwriters for the
          reasonable fees and expenses of their counsel and for such other out-of-pocket expenses as shall have been reasonably incurred by them in connection with this Agreement and the proposed purchase of the Shares, and upon demand, CareTrust and the
          Operating Partnership shall pay the full amount thereof to the Underwriters.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;">Notices</font>.&#160; All statements, requests, notices and agreements hereunder shall be in writing, and:</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">29</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman';">if to the Underwriters, shall be
          delivered or sent by mail, telex or facsimile transmission to: J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179 <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(fax: (212) 622-8358); Attention Equity
            Syndicate Desk; BofA Securities, Inc., One Bryant Park, New York, New York 10036, Attention: Syndicate Department (Email: <u>dg.ecm_execution_services@bofa.com</u>) with a copy to ECM Legal (Email: dg.ecm_legal@bofa.com); and RBC Capital
            Markets, LLC, 200 Vesey Street, 8th Floor, New </font>York, NY 10281-8098, Attention:&#160; Equity Syndicate (Email: Dan.King@rbccm.com); and with a copy (which shall not constitute notice) to Jones Day, 901 Lakeside Avenue, Cleveland, Ohio 44114,
          Attention: Michael J. Solecki, Esq. (Facsimile: 216-579-0212; Telephone: 216-586-7103); and</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-family: 'Times New Roman';">if to CareTrust or the Operating
          Partnership, shall be delivered or sent by mail or facsimile transmission to it at 905 Calle Amanecer, Suite 300, San Clemente, California 92673, Attention: William M. Wagner, Chief Financial Officer (Facsimile: 949-540-3002&#894; Telephone:
          949-542-3133)&#894; with a copy (which shall not constitute notice) to O&#8217;Melveny &amp; Myers LLP, 610 Newport Center Drive, Suite 1700, Newport Beach, CA 92660, Attention: Shelly Heyduk (Facsimile: 949-823-6994&#894; Telephone: 949-823-7968).</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Any notice of a change of address or facsimile transmission number must be given by CareTrust or the Underwriters, as the case maybe, in writing at
      least three days in advance of such change.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">12.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;">Persons Entitled to Benefit of Agreement</font>.&#160; This Agreement shall inure to the benefit of and be binding upon the Underwriters, CareTrust, the Operating Partnership and their respective successors.&#160; This
          Agreement and the terms and provisions hereof are for the sole benefit of only those persons, except that (a) the representations, warranties, indemnities and agreements of CareTrust and the Operating Partnership contained in this Agreement shall
          also be deemed to be for the benefit of the officers and employees of each Underwriter, its affiliates, their respective officers, directors, employees and agents, and each person, if any, who controls such indemnified party within the meaning of
          Section 15 of the Securities Act or Section 20 of the Exchange Act and (b) the representations and warranties of the Underwriters in this Agreement and the indemnity agreement of the Underwriters contained in <font style="font-family: 'Times New Roman';"><u>Section 7(b)</u></font> hereof shall be deemed to be for the benefit of directors, officers and employees of CareTrust and the Operating Partnership, and any person controlling CareTrust within the meaning of Section 15 of the
          Securities Act or Section 20 of the Exchange Act.&#160; Nothing contained in this Agreement is intended or shall be construed to give any person, other than the persons referred to in this <font style="font-family: 'Times New Roman';"><u>Section 12</u></font>,
          any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">13.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;">Survival</font>.&#160; The respective indemnities, representations, warranties and agreements of CareTrust and the Operating Partnership and the Underwriters contained in this Agreement or made by or on behalf of them,
          respectively, pursuant to this Agreement, shall survive the delivery of and payment for the Shares and shall remain in full force and effect, regardless of any termination or cancellation of this Agreement or any investigation made by or on
          behalf of any of them or any person controlling any of them.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">30</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">14.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;">Absence of Fiduciary Relationship</font>.&#160; Each of CareTrust and the Operating Partnership acknowledges and agrees that (i) the purchase and sale of the Shares pursuant to this Agreement, including the determination
          of the terms of the offering and any related discounts and commissions, is an arm&#8217;s-length commercial transaction between CareTrust and the Operating Partnership, on the one hand, and the several Underwriters, on the other, (ii) in connection
          therewith and with the process leading to such transaction, each Underwriter is acting solely as a principal and not the agent or fiduciary of CareTrust or the Operating Partnership, or their respective security holders, creditors, employees or
          any other party, (iii) no Underwriter has assumed, nor will it assume, any advisory or fiduciary responsibility in favor of CareTrust or the Operating Partnership with respect to the offering contemplated hereby or the process leading thereto
          (irrespective of whether such Underwriter or its affiliates has advised or is currently advising CareTrust or the Operating Partnership on other matters) or any other obligation to CareTrust or Operating Partnership except the obligations
          expressly set forth in this Agreement, (iv) the Underwriters and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of CareTrust and the Operating Partnership and (v) the
          Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the offering contemplated by this Agreement and CareTrust and the Operating Partnership consulted its own legal, accounting, regulatory, tax and
          financial advisors to the extent it deemed appropriate.&#160; Each of CareTrust and the Operating Partnership agrees that it will not claim that the Underwriters, or any of them, has rendered advisory services of any nature or respect, or owes a
          fiduciary or similar duty to CareTrust or the Operating Partnership, in connection with such transaction or the process leading thereto.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">15.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;">Governing Law</font>.&#160; THIS AGREEMENT AND ANY DISPUTE, CLAIM OR CONTROVERSY ARISING UNDER OR RELATED TO THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.&#160; Each
          party hereto hereby irrevocably submits for purposes of any action arising from this Agreement brought by the other party hereto to the jurisdiction of the courts of New York State located in the Borough of Manhattan and the U.S. District Court
          for the Southern District of New York.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">16.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;">Recognition of U.S. Special Resolution Regimes</font>.&#160;&#160; In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such
          Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest
          and obligation, were governed by the laws of the United States or a state of the United States.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160; (i)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">In the event that any Underwriter
          that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be
          exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">31</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">As used in this Section 16, the term &#8220;BHC Act Affiliate&#8221; has the meaning assigned to the term &#8220;affiliate&#8221; in, and shall be interpreted in accordance
      with, 12 U.S.C. &#167; 1841(k)&#894; the term &#8220;Covered Entity&#8221; means any of the following: (i) a &#8220;covered entity&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b)&#894; (ii) a &#8220;covered bank&#8221; as that term is defined in, and
      interpreted in accordance with, 12 C.F.R. &#167; 47.3(b)&#894; or (iii) a &#8220;covered FSI&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b)&#894; the term &#8220;Default Right&#8221; has the meaning assigned to that term in, and shall be
      interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable&#894; and the term &#8220;U.S. Special Resolution Regime&#8221; means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the
      Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">17.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;">Counterparts</font>.&#160; This Agreement may be executed in one or more counterparts and, if executed in more than one counterpart, the executed counterparts shall each be deemed to be an original but all such
          counterparts shall together constitute one and the same instrument.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">18.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;">Headings</font>.&#160; The headings herein are inserted for convenience of reference only and are not intended to be part of, or to affect the meaning or interpretation of, this Agreement.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">19.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;">Waiver of Jury Trial</font>.&#160; Each of CareTrust, the Operating Partnership and the Underwriters hereby irrevocably waives any right it may have to a trial by jury in respect of any claim based upon or arising out of
          this Agreement or the transactions contemplated hereby or thereby.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">32</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">If the foregoing correctly sets forth the agreement between CareTrust and the Operating Partnership and the Underwriters, please indicate your
      acceptance in the space provided for that purpose below.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="z1fed78a3feaa4318a8bf9d72da7f20e9" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 49.94%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
          <td style="vertical-align: top; font-size: 10pt;" colspan="3" rowspan="1">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Very truly yours,</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.94%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
          <td style="vertical-align: top; font-size: 10pt;" colspan="3" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.94%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="vertical-align: top; font-size: 10pt;" colspan="3">
            <div style="text-align: left; font-family: 'Times New Roman'; font-weight: bold;">CARETRUST REIT, INC.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.94%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 30%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 15%; vertical-align: top; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.94%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
          <td style="vertical-align: top; font-size: 10pt; width: 5%; padding-bottom: 2px;">
            <div style="text-align: left; font-family: 'Times New Roman';">By:&#160; &#160; &#160;&#160;</div>
          </td>
          <td style="vertical-align: top; border-bottom: 2px solid black; font-size: 10pt; width: 30%;" rowspan="1"> <font style="font-family: 'Times New Roman';">/s/ William M. Wagner</font>&#160;</td>
          <td style="vertical-align: top; font-size: 10pt; width: 15%; padding-bottom: 2px;">&#160;</td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Name:</div>
          </td>
          <td style="width: 40%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">William M. Wagner</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Title:</div>
          </td>
          <td style="width: 40%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Chief Financial Officer and Treasurer</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 49.94%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 30%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 15%; vertical-align: top; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.94%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="vertical-align: top; font-size: 10pt;" colspan="3">
            <div style="text-align: left; font-family: 'Times New Roman'; font-weight: bold;">CTR PARTNERSHIP, L.P.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.94%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 30%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 15%; vertical-align: top; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.94%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">By:</div>
          </td>
          <td style="vertical-align: top; font-size: 10pt; width: 30%;" rowspan="1">
            <div style="text-align: left; font-family: 'Times New Roman';">CareTrust GP, LLC, its general partner</div>
          </td>
          <td style="vertical-align: top; font-size: 10pt; width: 15%;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.94%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 30%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 15%; vertical-align: top; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.94%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">By:</div>
          </td>
          <td style="vertical-align: top; font-size: 10pt;" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman';">CareTrust REIT, Inc., its sole member</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.94%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 30%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 15%; vertical-align: top; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.94%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
          <td style="vertical-align: top; font-size: 10pt; padding-bottom: 2px; width: 5%;">
            <div style="text-align: left; font-family: 'Times New Roman';">By:</div>
          </td>
          <td style="vertical-align: top; border-bottom: 2px solid black; font-size: 10pt; width: 30%;"><font style="font-family: 'Times New Roman';">/s/ William M. Wagner</font></td>
          <td style="vertical-align: top; font-size: 10pt; width: 15%; padding-bottom: 2px;">&#160;</td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Name:</div>
          </td>
          <td style="width: 40%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">William M. Wagner</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Title:</div>
          </td>
          <td style="width: 40%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Chief Financial Officer and Treasurer</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt; font-style: normal; font-variant: normal; text-transform: none;">
          <div style="text-align: center;">[Signature Page to Underwriting Agreement]</div>
        </div>
      </div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Accepted and agreed by:</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">J.P. MORGAN SECURITIES LLC</div>
    <div style="text-align: left; margin-left: 40.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Acting as Representative of the</div>
    <div style="text-align: left; margin-left: 40.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Several Underwriters named</div>
    <div style="text-align: left; margin-left: 40.5pt; font-family: 'Times New Roman'; font-size: 10pt;">in attached Schedule I</div>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="z16657de107684a1dace9afc4c3bd2cf2" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 3%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
            <div style="text-align: left; font-family: 'Times New Roman';">By:<font style="font-family: 'Times New Roman';"><br>
              </font></div>
          </td>
          <td style="width: 37%; vertical-align: top; border-bottom: 2px solid black; font-size: 10pt;"><font style="font-family: 'Times New Roman';">/s/ Haley Trethaway</font></td>
          <td style="width: 60%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 7%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 93%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Name: Haley Trethaway</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 93%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Title: Managing Director</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt; font-style: normal; font-variant: normal; text-transform: none;">
          <div style="text-align: center;">[Signature Page to Underwriting Agreement]</div>
        </div>
      </div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Accepted and agreed by:</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">BOFA SECURITIES, INC.</div>
    <div style="text-align: left; margin-left: 40.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Acting as Representative of the</div>
    <div style="text-align: left; margin-left: 40.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Several Underwriters named</div>
    <div style="text-align: left; margin-left: 40.5pt; font-family: 'Times New Roman'; font-size: 10pt;">in attached Schedule I</div>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zee2725e65bb24ef28c5eede266982a96" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 3%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
            <div style="text-align: left; font-family: 'Times New Roman';">By:<font style="font-family: 'Times New Roman';"><br>
              </font></div>
          </td>
          <td style="width: 37%; vertical-align: top; border-bottom: 2px solid black; font-size: 10pt;"><font style="font-family: 'Times New Roman';">/s/ Andreas Apostolatos</font></td>
          <td style="width: 60%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 7%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 93%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Name: Andreas Apostolatos</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 93%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Title: Managing Director</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt; font-style: normal; font-variant: normal; text-transform: none;">
          <div style="text-align: center;">[Signature Page to Underwriting Agreement]</div>
        </div>
      </div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" class="BRPFPageHeader"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Accepted and agreed by:</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">RBC CAPITAL MARKETS, LLC</div>
    <div style="text-align: left; margin-left: 40.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Acting as Representative of the</div>
    <div style="text-align: left; margin-left: 40.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Several Underwriters named</div>
    <div style="text-align: left; margin-left: 40.5pt; font-family: 'Times New Roman'; font-size: 10pt;">in attached Schedule I</div>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="z7494d9150e5c4763849920fac5750dc6" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 3%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
            <div style="text-align: left; font-family: 'Times New Roman';">By:<font style="font-family: 'Times New Roman';"><br>
              </font></div>
          </td>
          <td style="width: 47%; vertical-align: top; border-bottom: 2px solid black; font-size: 10pt;"><font style="font-family: 'Times New Roman';">/s/ J.T. Deignan</font></td>
          <td style="width: 50%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;"><br>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 7%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 93%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Name: J.T. Deignan</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 93%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Title: Managing Director</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter">
        <div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 8pt; font-style: normal; font-variant: normal; text-transform: none;">
          <div style="text-align: center;">[Signature Page to Underwriting Agreement]</div>
        </div>
      </div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: right; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>SCHEDULE I</u></div>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="zfcbbe6946d074e0b979d4af42ea34a42" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td colspan="1" style="width: 5%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">&#160;</td>
          <td style="width: 49%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Underwriter</div>
          </td>
          <td style="width: 11.12%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 34.74%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Number of</div>
            <div style="text-align: center; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Firm Shares to be</div>
            <div style="text-align: center; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Purchased</div>
          </td>
        </tr>
        <tr>
          <td colspan="1" style="width: 5%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 49%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 11.12%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 34.74%; vertical-align: top; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td colspan="1" style="width: 5%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 49%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">J.P. Morgan Securities LLC</div>
          </td>
          <td style="width: 11.12%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 34.74%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">3,600,000</div>
          </td>
        </tr>
        <tr>
          <td colspan="1" style="width: 5%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 49%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">BofA Securities, Inc.</div>
          </td>
          <td style="width: 11.12%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 34.74%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">3,400,000</div>
          </td>
        </tr>
        <tr>
          <td colspan="1" style="width: 5%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 49%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">RBC Capital Markets, LLC</div>
          </td>
          <td style="width: 11.12%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 34.74%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">3,400,000</div>
          </td>
        </tr>
        <tr>
          <td colspan="1" style="width: 5%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 49%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Wells Fargo Securities, LLC</div>
          </td>
          <td style="width: 11.12%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 34.74%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">2,400,000</div>
          </td>
        </tr>
        <tr>
          <td colspan="1" style="width: 5%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 49%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">BMO Capital Markets Corp.</div>
          </td>
          <td style="width: 11.12%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 34.74%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">1,900,000</div>
          </td>
        </tr>
        <tr>
          <td colspan="1" style="width: 5%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 49%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">KeyBanc Capital Markets Inc.</div>
          </td>
          <td style="width: 11.12%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 34.74%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">1,600,000</div>
          </td>
        </tr>
        <tr>
          <td colspan="1" style="width: 5%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 49%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Morgan Stanley &amp; Co. LLC</div>
          </td>
          <td style="width: 11.12%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 34.74%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">1,600,000</div>
          </td>
        </tr>
        <tr>
          <td colspan="1" style="width: 5%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 49%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Huntington Securities, Inc.</div>
          </td>
          <td style="width: 11.12%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 34.74%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">700,000</div>
          </td>
        </tr>
        <tr>
          <td colspan="1" style="width: 5%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 49%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">M&amp;T Securities, Inc.</div>
          </td>
          <td style="width: 11.12%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 34.74%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">700,000</div>
          </td>
        </tr>
        <tr>
          <td colspan="1" style="width: 5%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 49%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Raymond James &amp; Associates, Inc</div>
          </td>
          <td style="width: 11.12%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 34.74%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">700,000</div>
          </td>
        </tr>
        <tr>
          <td colspan="1" style="width: 5%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 49%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 11.12%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 34.74%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td colspan="1" style="width: 5%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 49%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold; margin-left: 36pt;">Total</div>
          </td>
          <td style="width: 11.12%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 34.74%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">20,000,000</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: right; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>SCHEDULE II</u></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Materials other than the Time of Sale Prospectus that comprise the Disclosure Package:</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Price to public $32.00 per share.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Offering size of 20,000,000 Firm Shares (not including Optional Shares that may be purchased at the option of the Underwriters)</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: right; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>SCHEDULE III</u></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Issuer Free Writing Prospectuses not included in the Disclosure Package:</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Net Road Show presentation, dated August 12, 2025.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: right; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Exhibit A</u></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">FORM OF LOCK-UP LETTER AGREEMENT</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: right; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">August <font style="font-family: 'Times New Roman';"><u>___</u></font>, 2025</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">J.P. Morgan Securities LLC</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">BofA Securities, Inc.</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">RBC Capital Markets, LLC</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">As Representatives of the several Underwriters</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">c/o J.P. Morgan Securities LLC</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">383 Madison Avenue</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">New York, New York 10179</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Ladies and Gentlemen:</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The undersigned understands that you, as Representatives (collectively, the &#8220;Representatives&#8221;) of the several underwriters (collectively, the
      &#8220;Underwriters&#8221;), propose to enter into an Underwriting Agreement (the &#8220;Underwriting Agreement&#8221;) with CareTrust REIT, Inc., a Maryland corporation (&#8220;CareTrust&#8221;), and CTR Partnership, L.P., a Delaware limited partnership (the &#8220;Operating Partnership&#8221;),
      providing for a public offering (the &#8220;Offering&#8221;) of shares of the common stock of CareTrust, par value $0.01 per share (the &#8220;Common Stock&#8221;).&#160; The undersigned recognizes that the Offering will be of benefit to the undersigned and will benefit
      CareTrust and the Operating Partnership.&#160; The undersigned acknowledges that CareTrust, the Operating Partnership, you and the other Underwriters will proceed with the Offering in reliance on this Lock-Up Letter Agreement.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">In consideration of the foregoing, the undersigned hereby agrees that the undersigned will not (and will cause any spouse or immediate family member
      of the spouse or the undersigned living in the undersigned&#8217;s household not to), without the prior written consent of the Representatives (which consent may be withheld in their sole discretion), directly or indirectly, sell, offer, contract or grant
      any option to sell (including, without limitation, any short sale), pledge, transfer, establish an open &#8220;put equivalent position&#8221; within the meaning of Rule 16a-1(h) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or
      otherwise dispose of any shares of Common Stock, options or warrants to acquire shares of Common Stock, or securities exchangeable or exercisable for or convertible into shares of Common Stock currently or hereafter owned either of record or
      beneficially (as defined in Rule 13d-3 under the Exchange Act) by the undersigned (or such spouse or family member), or publicly announce an intention to do any of the foregoing, for a period commencing on the initial filing date of the preliminary
      prospectus supplement used to sell the shares of Common Stock in the Offering filed pursuant to Rule 424(b) of the Securities Act of 1933, as amended (the &#8220;Act&#8221;), and continuing through the close of trading on the date 45 days after the date of the
      final prospectus supplement used to sell the shares of Common Stock in the Offering filed pursuant to Rule 424(b) under the Act (the &#8220;Lock-Up Period&#8221;).&#160; The foregoing sentence shall not apply to:</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-family: 'Times New Roman';">transfers of shares of Common Stock
          or any security convertible into or exercisable or exchangeable for shares of Common Stock (i) as a bona fide gift, including to charitable organizations, or by will or intestacy, (ii) to the spouse, parent, sibling, child or grandchild of the
          undersigned or any other person with whom the undersigned has a relationship by blood, marriage or adoption not more remote than first cousin (each, &#8220;an immediate family member&#8221;) or to a trust, or other entity formed for estate planning purposes,
          formed for the benefit of the undersigned or of an immediate family member of the undersigned, (iii) if the undersigned is a corporation or partnership or limited liability company or other business entity, to another corporation, partnership,
          limited liability company or other business entity that controls, is controlled by or is under common control with the undersigned, (iv) if the undersigned is a trust, to a trustor or beneficiary of the trust or (v) not involving a change in
          beneficial ownership&#894; provided that in the case of any transfer or distribution pursuant to this clause (a), (A) each transferee, donee or distributee shall sign and deliver a lock-up agreement substantially in the form of this Lock-Up Letter
          Agreement and (B) no filing under the Exchange Act, reporting a reduction of beneficial ownership of shares of Common Stock, shall be required (other than a filing on Form 5 required and filed after the expiration of the Lock-Up Period or, in the
          case of (i), (ii), (iii) or (iv) above, a filing on Form 4 if required to be made during the Lock-Up Period as a result of any applicable transfer) or shall be voluntarily made during the Lock-Up Period&#894;</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">distributions of shares of Common
          Stock or any security convertible into or exercisable or exchangeable for shares of Common Stock to limited partners or stockholders of the undersigned&#894; provided that in the case of any transfer or distribution pursuant to this clause (c), (A)
          each donee or distributee shall sign and deliver a lock-up agreement substantially in the form of this Lock-Up Letter Agreement and (B) no filing under the Exchange Act, reporting a reduction in beneficial ownership of shares of Common Stock,
          shall be required or shall be voluntarily made during the Lock-Up Period&#894;</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">the receipt by the undersigned from
          CareTrust of shares of Common Stock upon the vesting of stock units or stock awards issued pursuant to CareTrust&#8217;s equity incentive plans or the transfer of shares of Common Stock or any securities convertible into shares of Common Stock to
          CareTrust upon a vesting event of CareTrust&#8217;s securities or upon the exercise of options or warrants to purchase CareTrust&#8217;s securities (including settlement of restricted stock units), in each case on a &#8220;cashless&#8221; or &#8220;net exercise&#8221; basis or to
          cover tax withholding obligations of the undersigned in connection with such vesting or exercise, provided that any related filing under the Exchange Act required to be made during the Lock-Up Period shall indicate that such filing is being made
          in connection with a disposition to CareTrust to satisfy tax withholding requirements&#894;</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-family: 'Times New Roman';">the establishment of a written
          trading plan pursuant to Rule 10b5-1 under the Exchange Act during the Lock-Up Period for the transfer of shares of Common Stock, provided that (A) such plan does not provide for the transfer of shares of Common Stock during the Lock-Up Period
          and (B) no public announcement or filing under the Exchange Act shall be made during the Lock-Up Period by or on behalf of the undersigned or CareTrust regarding the establishment of such plan (other than a filing under the Exchange Act required
          and filed before the expiration of the Lock-Up Period)&#894;</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-family: 'Times New Roman';">if the undersigned is an individual,
          the transfer of shares of Common Stock or any security convertible into or exercisable or exchangeable for shares of Common Stock that occurs by operation of law pursuant to a qualified domestic order or in connection with a divorce settlement,
          provided that the undersigned shall use reasonable best efforts to cause the transferee to sign and deliver a lock-up agreement substantially in the form of this Lock-Up Letter Agreement, and provided further, that any filing under the Exchange
          Act that is required to be made during the Lock-Up Period as a result of such transfer, states (unless prohibited by law) that such transfer has occurred by operation of law and that such transfer is pursuant to a qualified domestic order or in
          connection with a divorce settlement, as applicable&#894; and</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(f)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">any transfer of shares of Common
          Stock or any security convertible into or exercisable or exchangeable for shares of Common Stock to a bona fide third party pursuant to a tender offer, merger, consolidation or other similar transaction made to all holders of the Common Stock
          involving a &#8220;change of control&#8221; (as defined below) of CareTrust following the Offering&#894; provided that in the event that the tender offer, merger, consolidation or other such transaction is not completed, the shares of Common Stock owned by the
          undersigned shall remain subject to the terms of this Lock-Up Letter Agreement.&#160; For purposes of this clause (f), &#8220;change of control&#8221; shall mean the consummation of any bona fide third party tender offer, merger, consolidation or other similar
          transaction the result of which is that any &#8220;person&#8221; (as defined in Section 13(d)(3) of the Exchange Act), or group of persons, other than CareTrust, becomes the beneficial owner (as defined in Rules 13d-3 and 13d-5 of the Exchange Act) of 50% of
          total voting power of the voting stock of the CareTrust.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The undersigned agrees and consents to the entry of stop transfer instructions with CareTrust&#8217;s transfer agent and registrar against the transfer of
      shares of Common Stock or securities convertible into or exchangeable or exercisable for shares of Common Stock held by the undersigned except in compliance with the foregoing restrictions.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">If for any reason the Offering or the Underwriting Agreement (other than the provisions thereof that survive termination) is terminated prior to the
      First Delivery Date (as defined in the Underwriting Agreement) pursuant to the provisions thereof, then the agreements set forth herein shall likewise be terminated and the undersigned shall be released from all obligations hereunder.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">This Lock-Up Letter Agreement is irrevocable and will be binding on the undersigned and the respective successors, heirs, personal representatives,
      and assigns of the undersigned.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The undersigned acknowledges and agrees that the Underwriters have not provided any recommendation or investment advice nor have the Underwriters
      solicited any action from the undersigned with respect to the Offering of the Common Stock and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to the extent deemed appropriate.&#160; The undersigned
      further acknowledges and agrees that, although the Representatives may be required or choose to provide certain Regulation Best Interest and Form CRS disclosures to you in connection with the Offering, the Representatives and the other Underwriters
      are not making a recommendation to you to enter into this Lock-Up Letter Agreement, and nothing set forth in such disclosures is intended to suggest that the Representatives or any Underwriter is making such a recommendation.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">THIS LOCK-UP LETTER AGREEMENT AND ANY DISPUTE, CLAIM OR CONTROVERSY ARISING UNDER OR RELATED TO THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN
      ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.&#160; The undersigned hereby irrevocably submits for purposes of any action arising from this Agreement brought by the Underwriters to the jurisdiction of the courts of New York State located in the
      Borough of Manhattan and the U.S. District Court for the Southern District of New York.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="z9ce4600f838d40b3954442f8b17cb98c" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 45%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
          <td style="width: 55%; vertical-align: top; font-size: 10pt;" rowspan="1">Very truly yours,</td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
          <td style="width: 55%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
          <td style="width: 55%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 55%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Name:</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 55%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Title:</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: right; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Exhibit B</u></div>
    <br>
    <div style="font-size: 10pt;">
      <table cellspacing="0" cellpadding="0" border="0" id="z3a8bc8d957d94664955d9c0921583639" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="vertical-align: top;" colspan="2">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Persons to Execute Lock-Up Letter Agreements:</u></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align: top;" colspan="2" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">1.</div>
            </td>
            <td style="width: 95%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">James B. Callister</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 95%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">2.</div>
            </td>
            <td style="width: 95%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">David M. Sedgwick</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 95%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">3.</div>
            </td>
            <td style="width: 95%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">William M. Wagner</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 95%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">4.</div>
            </td>
            <td style="width: 95%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Diana M. Laing</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 95%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">5.</div>
            </td>
            <td style="width: 95%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Anne Olson</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 95%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">6.</div>
            </td>
            <td style="width: 95%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Spencer G. Plumb</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 95%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">7.</div>
            </td>
            <td style="width: 95%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Careina D. Williams</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div> <br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
  <font style="font-size: 10pt;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ef20053958_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solution Inc.
         Document created using Broadridge PROfile 25.7.1.5324
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-size: 10pt;"> </font>
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div>
    <div style="text-align: right; text-indent: -188.65pt; margin-left: 188.65pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-weight: bold;"> Exhibit 5.1</font><br>
    </div>
    <div style="text-align: justify; text-indent: -188.65pt; margin-left: 188.65pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
      <table cellspacing="0" cellpadding="0" border="0" align="center" id="z030afb484d5d4a419694e1076c9eca26" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 50%; text-align: left; vertical-align: top;"><img src="image00003.jpg"></td>
            <td style="width: 50%;">
              <div style="text-align: left; margin-left: 144pt; font-family: 'Times New Roman'; font-size: 8pt; font-weight: bold;"><a name="zzmpFIXED_LHFirstPage"></a>DLA Piper LLP (US)</div>
              <div style="text-align: left; margin-left: 144pt; font-family: 'Times New Roman'; font-size: 8pt;">650 S Exeter Street<font style="font-size: 8pt; font-family: 'Times New Roman';"><br>
                </font>Suite 1100<font style="font-size: 8pt; font-family: 'Times New Roman';"><br>
                </font>Baltimore, Maryland&#160; 21202</div>
              <div style="text-align: left; margin-left: 144pt; font-family: 'Times New Roman'; font-size: 8pt;">www.dlapiper.com</div>
              <div><br>
              </div>
              <div style="text-align: left; margin-left: 144pt; font-family: 'Times New Roman'; font-size: 8pt;"><font style="font-size: 8pt; font-family: 'Times New Roman'; font-weight: bold;">T</font>&#160;&#160; 410.580.3000</div>
              <div style="text-align: left; margin-left: 144pt; font-family: 'Times New Roman'; font-size: 8pt;"><font style="font-size: 8pt; font-family: 'Times New Roman'; font-weight: bold;">F</font>&#160;&#160; 410.580.3001</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">August 14, 2025</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">CareTrust REIT, Inc.</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">905 Calle Amanecer, Suite 300</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">San Clemente, CA 92673</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Offering of Common Stock</u></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: -0.45pt; margin-left: 0.45pt; font-family: 'Times New Roman'; font-size: 10pt;">Ladies and Gentlemen:</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">We have served as special Maryland counsel to CareTrust REIT, Inc., a Maryland corporation (the &#8220;<font style="font-family: 'Times New Roman';"><u>Company</u></font>&#8221;),<font style="font-family: 'Times New Roman';">&#160;</font>and have been requested to render this opinion letter in connection with the registration under the Securities Act of 1933, as amended (the &#8220;<font style="font-family: 'Times New Roman';"><u>Securities
          Act</u></font>&#8221;), pursuant to <a name="z_cp_change_7"></a><a name="z_cp_change_8"></a>the automatic shelf registration statement of the Company on Form S-3 (Registration No. <a name="z_cp_change_9"></a><a name="z_cp_change_10"></a>333-<font style="font-family: 'Times New Roman';">&#160;</font>269998) (the &#8220;<font style="font-family: 'Times New Roman';"><u>Registration Statement</u></font>&#8221;), <a name="z_cp_change_11"></a><a name="z_cp_change_12"></a>prepared and filed by the Company on
      February 24, 2023 with the Securities and Exchange Commission (the &#8220;<font style="font-family: 'Times New Roman';"><u>Commission</u></font>&#8221;)<a name="z_cp_change_13"></a>, including the base prospectus included therein at the time the Registration
      Statement <a name="z_cp_change_14"></a><a name="z_cp_change_15"></a>became effective (the &#8220;<font style="font-family: 'Times New Roman';"><u>Base Prospectus</u></font>&#8221;), and the preliminary prospectus supplement, dated August 12, 2025, and filed by
      the Company with the Commission on<a name="z_cp_change_21"></a> August 12, 2025, pursuant to Rule 424(b)(5) under the Securities Act (together with the Base Prospectus, the &#8220;<font style="font-family: 'Times New Roman';"><u>Preliminary Prospectus</u></font>&#8221;),
      and the final prospectus supplement, dated August 12, 2025, and filed by the Company with the Commission on August 13, 2025 pursuant to Rule 424(b)(5) under the Securities Act (together with the Base Prospectus, the &#8220;<font style="font-family: 'Times New Roman';"><u>Prospectus</u></font>&#8221;), of the offering by the Company of an aggregate of (i) 20,000,000 shares (the &#8220;<font style="font-family: 'Times New Roman';"><u>Firm Shares</u></font>&#8221;) of common stock, par value $0.01 per share, of the
      Company (the &#8220;<font style="font-family: 'Times New Roman';"><u>Common Stock</u></font>&#8221;) and (ii) an additional 3,000,000 shares of Common Stock (the &#8220;<font style="font-family: 'Times New Roman';"><u>Optional Shares</u></font>,&#8221; and together with the
      Firm Shares, the &#8220;<font style="font-family: 'Times New Roman';"><u>Shares</u></font>&#8221;) pursuant to the option to purchase additional shares described in the Underwriting Agreement, dated as of August 12, 2025 (the &#8220;<font style="font-family: 'Times New Roman';"><u>Underwriting Agreement</u></font>&#8221;), by and among the Company and CTR Partnership, L.P., a Delaware limited partnership (the &#8220;<font style="font-family: 'Times New Roman';"><u>Operating Partnership</u></font>&#8221;), on the one hand, and
      <a name="z_cp_change_40"></a>J.P. Morgan Securities LLC, BofA Securities, Inc., RBC Capital Markets, LLC (collectively, the &#8220;<font style="font-family: 'Times New Roman';"><u>Representatives</u></font>&#8221;), as representatives of the several underwriters
      named on <font style="font-family: 'Times New Roman';"><u>Schedule I</u></font> to the Underwriting Agreement (collectively, the &#8220;<font style="font-family: 'Times New Roman';"><u>Underwriters</u></font>&#8221;), on the other hand. This opinion letter is
      being provided at your request in connection with the filing by the Company with the Commission of a Current Report on Form 8-K on the date hereof (the &#8220;<font style="font-family: 'Times New Roman';"><u>Form 8-K</u></font>&#8221;), and supplements our
      opinion, dated February 24, 2023, previously filed as Exhibit 5.2 to the Registration Statement. Capitalized terms used but not defined herein shall have the meanings specified in the Underwriting Agreement.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">In connection with our representation of the Company, and as a basis for the opinions hereinafter set forth, we have examined originals, or copies
      certified or otherwise identified to our satisfaction, of the following documents:</div>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z17fb32ba7fe743debd0eb54511b74b02">

        <tr>
          <td style="width: 36pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(a)</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">the Registration Statement;</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za73a4b44468644ea95d23ca15bbf9983">

        <tr>
          <td style="width: 36pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(b)</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">the Underwriting Agreement;</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd8eb0d7a9ca1494db41a726238c18a12">

        <tr>
          <td style="width: 36pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(c)</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">the Preliminary Prospectus;</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8aad88429072421a947cf96a813121c2">

        <tr>
          <td style="width: 36pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(d)</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">the Prospectus;</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5eed6e4845c04cbd80de1b6136b16761">

        <tr>
          <td style="width: 36pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(e)</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">the Articles of Amendment and Restatement of the Company as filed with the State Department of Assessments and Taxation of the State of Maryland (the &#8220;<font style="font-family: 'Times New Roman';"><u>SDAT</u></font>&#8221;)
              on and effective as of May 13, 2014, as amended by the Articles of Amendment to Articles of Amendment and Restatement of the Company as filed with the SDAT on and effective as of May 30, 2018 (collectively, the &#8220;<font style="font-family: 'Times New Roman';"><u>Charter</u></font>&#8221;);</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div class="BRPFPageHeader" style="width: 100%;">
        <div>
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">CareTrust REIT, Inc.</div>
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">August 14, 2025</div>
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Page 2</div>
        </div>
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z32424540780a4f8b9ed1cd20b97f8a39">

        <tr>
          <td style="width: 36pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(f)</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">the Company&#8217;s Amended and Restated Bylaws, as certified by the Secretary of the Company, as of the date hereof;</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc4499ddbb49847188e897997df3b7244">

        <tr>
          <td style="width: 36pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(g)</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">resolutions of the Board of Directors of the Company (the &#8220;<font style="font-family: 'Times New Roman';"><u>Board Resolutions</u></font>&#8221;) relating to the authorization and issuance of the Shares and
              the authorization of the Underwriting Agreement and the appointment and establishment of a Securities Committee of the Board of Directors and the transactions contemplated thereby, certified by an officer of the Company;</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze82187447fec42d7b0439772fd6d3040">

        <tr>
          <td style="width: 36pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(h)</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">resolutions of the Securities Committee of the Board of Directors of the Company (the &#8220;<font style="font-family: 'Times New Roman';"><u>Securities Committee Resolutions</u></font>&#8221; and together with
              the Board Resolutions, the &#8220;<font style="font-family: 'Times New Roman';"><u>Resolutions</u></font>&#8221;) relating to the authorization of the issuance and sale of the Shares, the selection of the Underwriters and approval of the Underwriting
              Agreement;</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2bfec49b027c4e3cb4ba237f6fe53a98">

        <tr>
          <td style="width: 36pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(i)</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">an executed copy of the certificate of an officer of the Company, dated as of the date hereof, as to certain factual matters;</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z466af90b9a02413f908a7b064f375be8">

        <tr>
          <td style="width: 36pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(j)</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">the certificate of the SDAT as to the existence and good standing of the Company in the State of Maryland dated as of a recent date (the &#8220;<font style="font-family: 'Times New Roman';"><u>Good
                  Standing Certificate</u></font>&#8221;); and</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9ebd721ee3a4496e9e56051666f7d58e">

        <tr>
          <td style="width: 36pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(k)</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">such other documents as we have deemed necessary or appropriate to enable us to express the opinions set forth below.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 1.65pt; font-family: 'Times New Roman'; font-size: 10pt;">For purposes of the opinions expressed below, we have assumed (i) the authenticity of all documents submitted to us as originals,
      (ii) the conformity to the originals of all documents submitted as certified or photostatic copies and the authenticity of the originals of such documents, (iii) the legal capacity of natural persons, (iv) the genuineness and validity of all
      signatures (including all signatures via DocuSign, eSignature or similar technology), (v) the due authorization, execution and delivery of all documents by all parties and the validity and binding effect and enforceability thereof upon the Company
      and (vi) the conformity of the documents filed with the Commission via the Electronic Data Gathering and Retrieval System, as supplemented by its Interactive Data Electronic Applications system (&#8220;<font style="font-family: 'Times New Roman';"><u>EDGAR</u></font>&#8221;),
      except for required EDGAR formatting changes, to physical copies of the documents prepared by the Company and submitted for our examination.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 1.65pt; font-family: 'Times New Roman'; font-size: 10pt;">Based upon the foregoing, and having regard for such legal considerations as we have considered necessary for purposes hereof, we
      are of the opinion that:</div>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z07625b2af90c4908ab0e02022a995b72">

        <tr>
          <td style="width: 36pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(1)</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">the Company is a corporation validly existing under the laws of the State of Maryland and is in good standing with the SDAT, and has the requisite corporate power to issue the Shares; and</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z32d04be67a0945a3acba7696c183a274">

        <tr>
          <td style="width: 36pt; font-size: 10pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(2)</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';">the Shares have been duly authorized and, when and to the extent issued against payment therefor in accordance with the terms of the Underwriting Agreement, the Resolutions, the Registration
              Statement and the Prospectus, will be validly issued and fully paid and non-assessable.</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The opinions in paragraph 1 with respect to existence and good standing of the Company are based solely on the Good Standing Certificate.&#160; In
      expressing the opinions above, we have assumed (i) that the Shares will not be issued or sold in violation of Article VII of the Charter and (ii) that, upon issuance of the Shares, the total number of shares of Common Stock issued and outstanding
      will not exceed the total number of shares of Common Stock that the Company is then authorized to issue under the Charter.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The opinions expressed above are subject to the following assumptions, exceptions, qualifications and limitations:</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(A)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">We have made no investigation of, and
          we express no opinion as to, the laws of any jurisdiction other than the laws of the State of Maryland. This opinion letter concerns only the effect of the laws (exclusive of the principles of conflict of laws) of the State of Maryland as
          currently in effect.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageFooter" style="width: 100%;"></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div class="BRPFPageHeader" style="width: 100%;">
        <div>
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">CareTrust REIT, Inc.</div>
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">August 14, 2025</div>
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Page 3<br>
          </div>
        </div>
      </div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(B)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">We express no opinion as to compliance
          with the securities (or &#8220;blue sky&#8221;) laws of any jurisdiction or as to federal or state tax laws or laws regarding fraudulent transfers.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(C)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">The foregoing opinions are rendered as
          of the date hereof. We assume no obligation to update such opinions to reflect any facts or circumstances that may hereafter come to our attention or that may hereafter occur.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(D)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">This opinion letter is limited to the
          matters set forth herein, and no other opinion should be inferred beyond the matters expressly stated.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 0.7pt; font-family: 'Times New Roman'; font-size: 10pt;">We hereby consent to the filing of this opinion letter as Exhibit 5.1 to the Form 8-K on the date hereof and to the use of the
      name of our firm in the section entitled &#8220;Legal Matters&#8221; in the Prospectus. In giving this consent, we do not admit that we are within the category of persons whose consent is required by Section 7 of the Securities Act or the rules and regulations
      promulgated thereunder by the Commission.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z2ee4a6d4456f47f19bb061bddeb3e10e">

        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">Very truly yours,</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold;">DLA Piper LLP (US)</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td rowspan="1" style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman';">/s/ DLA Piper LLP (US)</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
  <font style="font-size: 10pt;"> </font>
  <div class="BRPFPageFooter" style="width: 100%;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>ctre-20250814.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.7.1.5324 Broadridge-->
<xs:schema targetNamespace="http://caretrustreit.com/20250814" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:ctre="http://caretrustreit.com/20250814" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:srt-types="http://fasb.org/srt-types/2025">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="ctre-20250814_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ctre-20250814_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://caretrustreit.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2025" schemaLocation="https://xbrl.sec.gov/currency/2025/currency-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2025" schemaLocation="https://xbrl.sec.gov/exch/2025/exch-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2025" schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>ctre-20250814_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.7.1.5324 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract" xml:lang="en-US" id="dei_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract" xlink:title="label: CoverAbstract to dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType" xml:lang="en-US" id="dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType" xlink:title="label: DocumentType to dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications" xml:lang="en-US" id="dei_WrittenCommunications">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications" xlink:title="label: WrittenCommunications to dei_WrittenCommunications" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial" xml:lang="en-US" id="dei_SolicitingMaterial">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer" xml:lang="en-US" id="dei_PreCommencementTenderOffer">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag" xml:lang="en-US" id="dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag" xlink:title="label: AmendmentFlag to dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus" xml:lang="en-US" id="dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate" xml:lang="en-US" id="dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName" xml:lang="en-US" id="dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey" xml:lang="en-US" id="dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber" xml:lang="en-US" id="dei_EntityFileNumber">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber" xlink:title="label: EntityFileNumber to dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1" xml:lang="en-US" id="dei_EntityAddressAddressLine1">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2" xml:lang="en-US" id="dei_EntityAddressAddressLine2">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3" xml:lang="en-US" id="dei_EntityAddressAddressLine3">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown" xml:lang="en-US" id="dei_EntityAddressCityOrTown">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince" xml:lang="en-US" id="dei_EntityAddressStateOrProvince">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry" xml:lang="en-US" id="dei_EntityAddressCountry">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode" xml:lang="en-US" id="dei_EntityAddressPostalZipCode">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode" xml:lang="en-US" id="dei_CityAreaCode">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode" xlink:title="label: CityAreaCode to dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber" xml:lang="en-US" id="dei_LocalPhoneNumber">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle" xml:lang="en-US" id="dei_Security12bTitle">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle" xlink:title="label: Security12bTitle to dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag" xml:lang="en-US" id="dei_NoTradingSymbolFlag">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol" xml:lang="en-US" id="dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol" xlink:title="label: TradingSymbol to dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName" xml:lang="en-US" id="dei_SecurityExchangeName">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>ctre-20250814_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.7.1.5324 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://caretrustreit.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="ctre-20250814.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://caretrustreit.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image00003.jpg
<TEXT>
begin 644 image00003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !& '@# 2(  A$! Q$!_\0
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I3Q#C!66A]SE%6=7"J4W=ZA1117GGIA1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 14, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 14,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CareTrust REIT, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001590717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-3999490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">905 Calle Amanecer, Suite 300,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Clemente<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">542-3130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CTRE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ef20053958_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://caretrustreit.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ctre-20250814.xsd</File>
    <File>ctre-20250814_lab.xml</File>
    <File>ctre-20250814_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ef20053958_8k.htm">ef20053958_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ef20053958_8k.htm": {
   "nsprefix": "ctre",
   "nsuri": "http://caretrustreit.com/20250814",
   "dts": {
    "schema": {
     "local": [
      "ctre-20250814.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/exch/2025/exch-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ctre-20250814_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ctre-20250814_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ef20053958_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://caretrustreit.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20250814to20250814",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20053958_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250814to20250814",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20053958_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001140361-25-031253-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-25-031253-xbrl.zip
M4$L#!!0    ( +B##EM!N*PI1P,  $@/   1    8W1R92TR,#(U,#@Q-"YX
M<V2U5VUOTS 0_H[$?S#Y[KST!=9JW03:AB8-A@9(?$.N<VDM4B?8SM;^>VPG
M3M-7F@:^.;Y[GGM\OG.OE]?+18J>04B6\8D7^:&'@-,L9GPV\0J)B:2,>==7
MKU]=OL'X(W 01$&,IBOT060D%BR> ?KR])BP%%!OZ+_S(W_8[PT:9HP-?"G'
MDLYA09 B8@;J,UF S F%B3=7*A\' 24"E"BD$L"43[-%T M[P_ B&FA1*2R
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MN)](Z+24/%(\M?PDSY,Q-)#>D"R)0D[\" 1\5IXG:8]8\X45@M#MS:V&*-7
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MO2P'B(,8?.K#Z-,P!VW]%0R&R*%4U0%E[(L1C8)2&X\S$5V)3-6BF/=*I<@
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MDQ&!-+4?-@4?+DJNDBPGX>H(/N&KG', 'YBF*=L#5?J/>5HW]!X3XH+/MZR
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MBTJF&2L+V,\!-JT 51"CX0V_9^Y1YA8TI:_&)/>YSGC#NBG+3'8#=)T8T7
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M\L>"1H*GT5Z,\[(<(94@&'3_F*.)8+,T1=+,D<,9+ATJE:8-2_)D2LS")LR
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M2LR\@=2>"NUIXR[F60HR+@-:*(]O6E;-18(QPIG4#J3%$+R;RCK1>9)-85=
M"O8==OH(@VQ%P](-@]9K64RN4J1(5YQZIU^&TDV)FNJ8A=U:WQ2K7]VK<%3
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MOY]B*Z@W7E&7.;&.PR61U!E[/82H,/%DNC73T1,;Z]AG=R.KC?VTCF<$,[
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M"/X+!VEP&?^5(S?TF--7_F/TNCS7(S*LH9WH:?PCDR_D9-P/N7TU4:>7U8@
MB&FM>=--,:2PIE/_NB$SV<>._L*$0Q&4&BM64B80PMA<8[R?1L(%<,XF<Q!<
M$Y_"J%0F5'(,96@%HP*72(GC+1^;;J@7J8,*+"&X.U" 8*G UK]$52$_<[;
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MX?NLRCW@F'V'?^"YE5M[W^MYWLQ]1<./T(B]2B4/A[[5&/MKYRE"*_B]XK#
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M2&UR Y+K8A<=O#HC7>X/?HLYCF25B'";4DF40&3P+JTZ$&Z5.>D$L0OFS_S
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M7J>,%8*->E(HF%12D"R;[#6\=QC I$TDWEIDY:1[!XNB0UEP$(1I<@E/O4K
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MM=1+-C/N^XX%5R FH\G) @IE/1MF,\]YPJK\CJBT[!YLS<2E>)F[RD)MNX8
M[D.>5/!9F2 _':G9IU)9A#9IG;K)T$,--$/E"D+T1H]>., 0E(V]VUK=$$2"
M_T$#38%J6\^*<>W,2&1-VG.D'LLC712LNX8V&B0?X>MP^V)1PJ(%N=U]]R;V
MSU1J.@D*[T[LLJ4-YK_L1+N<1?\ U+U@U/PJ]\91LVR=_>F8F;R%5(;J.\2=
M9OV(BO*)7/?7\PTVHU-20A%R7[&E!7:;NO<(6W Y]1'WO$:!&_$#%04JL/$E
M16FY0^9U8656IYODP1Z3#JO_CF;*9C3F05:3B)<E'[2?ZY(-"DZ;_C<=:VD<
MAZ6SG,Z;.<?($3*FR&4:QIF%(Y5:$('=%\E4'LKU"%'0[,53V$+$@L;DYD->
M:S)*F8%06[:?1#0YWAE8R3C$*1,56TFSY+ZEXSP;XK$$WTRHDF9E[7>/76_$
M;6N'#]EH/K2D7DHJPXO-<&_QD#E"+L==O@6SN$I ZXORR%QHO+4\F?CY%$08
M96.J]Q0;HO2ZD]'&(]>7]^R^R[*2,IWNOR^I<9)TQTBK_96GU:0W$JU\J(>B
MI^6IA4_7]9VY,G$VE="BJ&]^-'M6YR +^+3P3Z3+ZZ8L6\GMI<:%?U48(&7G
MJ*?8](Y4=%E@U1&&"9K4TU6RW<8\S,LAR3Y]X%"UF.P;#AL/I:@U9KPTT2+_
MLE_J\,2NN]\B+)L"'ZI"&QD7.);2TEJQD\ _N52&NP=*V4[ 32W15<=,IPCG
MW#%K>36J[MA'14J%JV6-D%-9L_WI>C^#;932.?3K17$3NY57OT;RC9-@T(=&
M_=,?W0K&WOI5;GWPFA %+"W.;)D5D8R!G]\6:154)9\CSP-L!"TNY\?\47I&
M(*VRK?P>E6GM$W.IV#J7X)*) \*J4E3C9)[C[.;Y3$5,QZ"IL(P)Q7E(GG9)
MS>(&*0CKV A):SJZO_<&!R\4UK&$\&UG2A9J*?Z"=?'. %@.X4E!\P N4GZF
ME(R)ZI&C5,E%BYE'ZC&6X7;9737J8 9+#%(S[O=4Z':GQ769[F5;3:EH/]WK
M0V,&IAC#;KYWCKU4NPSWL51CU_''%X_QQV5;]4#[>FU5"? A4-UR<5E/>1PR
M&/AN98:95\_RHSQ</4?(2B;7KP^+28I>C_4^QI-@L'Z=I;WR-\"SK(*,$!5Z
M9=THSETV2+WJ92M;EXTU+JS1G4RQ68<EHIHE"]J8?D>>>#N8%L2JY-UCR3,I
M0D:&DK(R^<J,>.OA5U66\!1@(7+YHO0 )D*6(AWC16B+7+TN[,L3AN:O?K<H
MAZY"+)>-++AJ:UU2+?>^7H8/8\\:3]'(*<.S(X7S&;@6(YQ@3HG[(5_Z)N)$
M33C!9H#!2Y-B#/P[DM@\N=Y"%-BLVE06^G8I8.?OVC"< N,F.G<.398DKTO_
MSV2=;9*.7F<S>R)3*KNKD!B&190/ $<&]W,$B._V.H6=2FH5FD43^@H1.0C7
M:20Z5M39R)#S:*/S]DY$9_E?ZR+ RKUI&H@+):1+)+,KTL:8N77'&3O O\/F
MVV9!Q%N 39[GMAN090YF$9(.[7"X)"9B_-C#GI48@!U@5",/:LVWZ<<UR_K.
M>6"BKD0^;ZKE<T+BN%ERT<'-WKG3?$34=B!C0R9-YE4'#G1=IR5J+HFX(B$[
MPCY3^3DUB*0-D7+;@K[:X$"B)V-7PN%#"&Z4A=LF_DDO%V0+4&)D6F)7IE&5
M748D+4,WU\)88NQKA>9(,!Y\4#E#<9X762/5J-0O)>IDVV=ML0SL9;;U)L>3
M_3";\+DNY_G(>)J_F4<Z#9*-O;!#[>'^;I0NUBN _WE!]JRSF0AUYPLI:( (
MIIGH*Q*6A]+;1@M.04K+$8F?^Q!K9NOW(\V8:49F#D^?TO0,*JYW-I;K#0#Y
MWE2M4:"7Y.M2"ZS3\@WL+YS5'HS*_:P!ZR4_9JEN#$VA?B<U1^T(.0>5O%J<
MA7>$-T=P=JE&%Q)M<) (4C7=9725/.WW#O<#,0@>/M+>&QH-K"Q%1G^2O.(]
M]FVHNMS([P<+AZI=<GGZZ5MWCRI+5JYAH2D"E32<T#YT SO9:E #$8_+' 8+
MR/6^1VSS%JI 3(YZZK,DB$#M>_L-"<_%/,LY&SFNDOEHGN,#X=-^7[#H8$4]
MQLD!G.O.:N;#3E"!'WVV"! 9%";DKX7IV@V0N5>6C/(Q'K?K>-S+QWC<LJW:
M)SO'RSVQ<VP/![PY-\>[U#K6K"BHGLTS*'TCAL(9<AF&_6O11BM(,5*>T&"E
M.YXI&@B3*UR ,IYS?851]4;U&S.6#7E!GCD<@?VXRX\)AYWOA3?2^H;NB OX
M^@7Z'06=7]*:_#952#;BA4&MJB\-&$?;V!Z1PXF3,?4T.!U_@-8VY>L*9.5/
M]O;L&)"Z_:0OH+T##4D?SXK<9+*3]+C:V7%XA!#R(WS+X_0PIH8XYK5+&;OQ
MU#P6C+_ C4U5)N7P4A/TS@C*0"EVOR01 1SU5IQR7Y#=#4N//G20RJ&[7MM0
M9K"$ :/'1J,W R8'@Y>Z*(NC;H'@RA@3">*-T$N9U#:1:UDB)=87DH_9\%,
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M,O\G&^L49(SEI)1%(><7=?&,L2UA@DM6 :J@35%0$A79Q^M9&^KA:A.>KE'
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MQMY18V>D5R'[KN<G,>+>]P6GH&&V]$Q:AWO-=!Y)_Z#"7,X&YQN#1O.HL6<
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MUK4(Q/5.LT52C .IH.O!Y%#FS2G+]E/40+J]0Y\J )K$#8PH5ZTYI<GD:@J
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M5=CU.K'K<"NQ"X/G')")IZ!P2=TK7 7!$L=2QF,II_O!<$]E/6D+_OZ8DY!
M\.L[64D\\4&MZ@0L*TZ>:7_$X\A/+@7R)?*:=%S]#%/T!,"6E7L0C4\/A[0S
M%=;YW__UCY]&OGU/'VZBJ0L?_@-02P,$%     @ N(,.6XSVJ5EP$P  !7$
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M$+^<<0%^52KR56]MOP8J.?QE/6];*X%@L:IKZ\(9X&B:"OY9^<LHNCS'7H.
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M'_2/'_X_4$L! A0#%     @ N(,.6T&XK"E' P  2 \  !$
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M,# U,SDU.%]E>#$M,2YH=&U02P$"% ,4    " "X@PY;C/:I67 3   %<0
M%               @ 'IP   968R,# U,SDU.%]E>#4M,2YH=&U02P4&
/  8 !@"( 0  B]0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>ef20053958_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ctre-20250814.xsd" xlink:type="simple"/>
    <context id="c20250814to20250814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590717</identifier>
        </entity>
        <period>
            <startDate>2025-08-14</startDate>
            <endDate>2025-08-14</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20250814to20250814"
      id="Fact_6fe9c59c3933434f9c12ded4eb59cb63">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20250814to20250814"
      id="Fact_108c278141424840a0514dab45f779db">0001590717</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="c20250814to20250814"
      id="Fact_0c76931bf96242c2a131651f32fc8f60">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20250814to20250814"
      id="Fact_fbf21a23a5704c10979f288eb909d041">2025-08-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20250814to20250814"
      id="Fact_6c35c70d7a8b4e33bf1273ce47bcf9b0">CareTrust REIT, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20250814to20250814"
      id="Fact_7e3d2ed42fd44208b805e0fa811d6c66">MD</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20250814to20250814"
      id="Fact_b7cba9d8b3bf47adbd14e58bfe6ae305">001-36181</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20250814to20250814"
      id="Fact_0fc09458aa3f43ad8ea4612948faecb1">46-3999490</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20250814to20250814"
      id="Fact_fe7f390b403d45c3b575298b9ce890c0">905 Calle Amanecer, Suite 300,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20250814to20250814"
      id="Fact_f3da7cf52af74c9ab11d402b0f7b0675">San Clemente</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20250814to20250814"
      id="Fact_7c6465b72e504c23ad86c4c8bfc42d15">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20250814to20250814"
      id="Fact_6a15c0b075e74694ad8c49cac6888e7c">92673</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20250814to20250814"
      id="Fact_525a64eed0ff4f7fa8697784555573c1">949</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20250814to20250814"
      id="Fact_c0f2d723d2eb41d9a5ebd8f46c9c3267">542-3130</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20250814to20250814"
      id="Fact_c5fb312bda6f40859e40de61132efc0f">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20250814to20250814"
      id="Fact_adc0f3a7ea20405098d1b19ef7bda725">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20250814to20250814"
      id="Fact_5358cc7fb39d49eb930209b18f2bf848">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20250814to20250814"
      id="Fact_e771263c17144f3eb54b77448767840a">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20250814to20250814"
      id="Fact_c079aa9dac6f4139b8505c9aa1e3b6fb">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20250814to20250814"
      id="Fact_6c7e4c887e8d49eeaa404d403832b43e">CTRE</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20250814to20250814"
      id="Fact_fa63714a2dab4acbb9adcc12580e10de">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20250814to20250814"
      id="Fact_4c16e78ec09746328ba07669746f3346">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
